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ABSTRACT OF THE DISSERTATION
GENETIC MARKERS, BIRTH CHARACTERISTICS, AND
CHILDHOOD LEUKEMIA RISK
by
Amy Kennedy
Florida International University, 2013
Miami, Florida
Professor Mehmet T. Dorak, Major Professor
The cause for childhood acute lymphoblastic leukemia (ALL) remains unknown,
but male gender is a risk factor, and among ethnicities, Hispanics have the highest risk. In
this dissertation, we explored correlations among genetic polymorphisms, birth
characteristics, and the risk of childhood ALL in a multi-ethnic sample in 161 cases and
231 controls recruited contemporaneously (2007-2012) in Houston, TX. We first
examined three lymphoma risk markers, since lymphoma and ALL both stem from
lymphoid cells. Of these, rs2395185 showed a risk association in non-Hispanic White
males (OR=2.8, P=0.02; Pinteraction=0.03 for gender), but not in Hispanics. We verified
previously known risk associations to validate the case-control sample. Mutations of HFE
(C282Y, H63D) were genotyped to test whether iron-regulatory gene (IRG) variants
known to elevate iron levels increase childhood ALL risk. Being positive for either
polymorphism yielded only a modestly elevated OR in males, which increased to 2.96
(P=0.01) in the presence of a particular transferrin receptor (TFRC) genotype for
rs3817672 (Pinteraction=0.04). SNP rs3817672 itself showed an ethnicity-specific
association (Pinteraction=0.02 for ethnicity). We then examined additional IRG SNPs
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(rs422982, rs855791, rs733655), which showed risk associations in males (ORs=1.52 to
2.60). A polygenic model based on the number of polymorphic alleles in five IRG SNPs
revealed a linear increase in risk (OR=2.00 per incremental change; P=0.002). Having
three or more alleles compared with none was associated with increased risk in males
(OR=4.12; P=0.004). Significant risk associations with childhood ALL was found with
birth length (OR=1.18 per inch, P=0.04), high birth weight (>4,000g) (OR=1.93,
P=0.01), and with gestational age (OR=1.10 per week, P=0.04). We observed a negative
correlation between HFE SNP rs9366637 and gestational age (P=0.005), again, stronger
in males (P=0.001) and interacting with TFRC (P<0.001; Pinteraction=0.05). Our results
showed that (i) ALL risk markers do not show universal associations across ethnicities or
between genders, (ii) IRG SNPs modify ALL risk presumably by their effects on iron
levels, (iii) a negative correlation between an HFE SNP and gestational age exists, which
implicates an iron-related mechanism. The results suggest that currently unregulated
supplemental iron intake may have implications on childhood ALL development.
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CHAPTER I
INTRODUCTION
Cancer is the second leading cause of death among children ages 1-14, surpassed
only by accidents [1]. Despite making up only a small percentage of the total cancer cases
in the United States, approximately 1 in 100 new cancers is a childhood cancer, and the
number of childhood cancer cases has increased gradually over the past few decades.
Acute lymphoblastic leukemia (ALL) is the most common leukemia among children
[2,3]. There are approximately 30-45 children per 1,000,000 affected by this malignancy
annually [4], making up 80% of all childhood leukemias [4,5], with a peak incidence
occurring between the ages of 2 and 5 [6]. The racial/ethnic variation in the incidence of
childhood ALL is well established [4,7]. The highest incidence rates are among Hispanic
populations [8-10], followed by non-Hispanic Whites, Asians, and then Blacks [4].
ALL is typically characterized by an excess amount of lymphoblasts. Instead of
maturing into functional lymphocytes, an abundance of stem cells develop into
lymphoblasts, which are immature, malignant white blood cells [11]. These nonfunctional leukemia cells accumulate quickly in the blood and bone marrow, reducing the
effectiveness of healthy bloods cells in fighting infection, and eventual spread to other
organs [12]. The most common subtype of ALL is B-cell precursor (BCP) ALL,
accounting for 70% of childhood ALL [3].
Great improvements have been made in the treatment of ALL. In the 1960s, the 5year survival rate was less than 10% [13]. This rate has continually increased from 77%
in 1985-1994 [13] to 87.5% in 2000-2004, and is now estimated to be greater than 90%
[14]. The increase in survival rates is due to the combination of better diagnostics through
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molecular and microarray testing, and better treatments individualized to patients [15].
Despite the improving prognosis, the incident rate of ALL has increased annually over
the past few decades, and the exact cause of the disease remains unknown in more than
90% of the cases [15]. Survivors of childhood leukemia also have an increased risk for
other malignancies later in life, and almost two thirds of all pediatric cancer survivors
suffer from at least one permanent side effect from their treatment [16], which
emphasizes the need for prevention methods.
There are a few well established risk factors for childhood ALL, including race,
sex, age peak, maternal age, and certain genetic disorders, including Down Syndrome,
[17-22], but the exact cause is unknown in more than 90% of the cases [15,19]. Table I
lists the established, suggestive, and controversial risk factors associated with childhood
ALL. Birth weight has been recognized consistently as a risk factor for childhood ALL
[23-36]. Less than 5% of diagnosed cases are associated solely with genetic defects [19],
therefore many researchers are exploring environmental links to the disease. Ionizing
radiation can increase the risk for ALL [28], although the relationship is more established
with acute myeloid leukemia (AML).
It is likely that increased risk for childhood ALL involves the combination of
environmental insults and genetic predisposition [37]. There have been several genome
wide association studies (GWAS) conducted to identify risk variants for childhood ALL
[38-40]. Table II lists the polymorphisms found to be statistically significant with
childhood ALL risk in GWAS.
Candidate gene studies have also yielded many risk associations [38], although
many have yet to be replicated. Variants located in the iron-related hemochromatosis
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(HFE) gene, rs1800562 (C282Y) and rs1799945 (H63D), have been associated with an
increase in birth weight and childhood ALL risk, in males only [35,41-44]. These two
variants are the major contributors to hereditary hemochromatosis (HH), an inherited
disorder causing iron overload, which may progress to cell and tissue damage [45].
Excess iron can cause cell stress and oxidative damage, and has been shown to increase
susceptibility to cancer [46-49]. Male carriers of the variants of the HFE gene in
particular have been shown to have an increased risk for numerous neoplasms [50]. The
biological plausibility behind excess iron being a risk factor for childhood ALL is one
worth pursuing, for both population health benefits and for scientific advancements.
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Table I. Risk factors for childhood acute lymphoblastic leukemia
Established
Sex

Suggestive
Maternal reproductive
history

Controversial
Maternal drug use

Age peak

Maternal alcohol use

Exposure to nonionizing
radiation

Race

Maternal diet

Parental chemical exposure

Birth weight

Miscarriage history

Household exposure to
pesticides

Down syndrome

Advanced maternal age

Parental smoking: prior
and during pregnancy

Genetic disorders

Being the first-born or only
child

Ionizing radiation

Post-natal use of
chloramphenicol

Sibling with leukemia,
brain tumor or Down
syndrome

8

Table II. Genetic associations with childhood leukemia risk previously established in
genome wide association studies*
SNP

PMID**

rs11978267

19684603

European ancestry

Chromosome
nucleotide position
chr7: 50466304

rs11155133

19684603

European ancestry

chr6: 141169825

Intergenic

rs9290663

19684603

European ancestry

chr3: 178429939

KCNMB2

rs12621643

19684603

European ancestry

chr2: 223917983

KCNE4

rs2191566

19684603

European ancestry

chr19: 44511389

ZNF230

rs1879352

19684603

European ancestry

chr18: 2498054

Intergenic

rs2089222

19684603

European ancestry

chr12: 117002658

KRTHB5

rs10849033

19684603

European ancestry

chr12: 4425122

C12orf5

rs10821936

19684603

European ancestry

chr10: 63723577

ARID5B

rs563507

19684603

European ancestry

chr10: 34817988

PARD3

rs7554607

19684603

European ancestry

chr1: 237266603

RYR2

rs10873876

19684603

European ancestry

chr1: 76772328

SIAT7C

rs6428370

19684603

European ancestry

chr1: 196844593

Intergenic

rs1881797

19684603

European ancestry

chr1: 247689532

OR2C3

rs4132601

19684604

European ancestry

chr7: 50470604

IKZF1

rs2239633

19684604

European ancestry

chr14: 23589057

CEBPE

rs7089424

19684604

European ancestry

chr10: 63752159

ARID5B

rs6140264
rs9388856,
rs9388857,
rs1360756
rs3776932

20189245

Korean

chr20: 7376354

HAO1

20189245

Korean

chr6: 131148863

EPB41L2

20189245

Korean

chr5: 109185988

MAN2A1

rs12105972

20189245

Korean

chr2: 76648560

C2orf3

rs920590

22076464

European ancestry

chr8: 19651161

INTS10

rs7738636

22076464

European ancestry

chr6: 77789808

Intergenic

rs282708

22076464

European ancestry

chr4: 59503726

Intergenic

rs17505102

22076464

European ancestry

chr3: 189401776

TP63

rs17505102
rs207954

22076464
22076464

European ancestry
European ancestry

chr3: 189401776
chr15: 92657373

TP63
SLCO3A1

rs7156960

22076464

European ancestry

chr14: 76703351

C14orf118

rs7156960

22076464

European ancestry

chr14: 76703351

C14orf118

rs1945213

22076464

European ancestry

chr11: 56175671

OR8U8

rs1945213

22076464

European ancestry

chr11: 56175671

OR8U8

rs3942852

22076464

European ancestry

chr11: 48115089

PTPRJ

rs17837497

23007406

Mixed

chr7: 139702593

TBXAS1

rs1496766

23007406

Mixed

Cchr7: 78331465

MAGI2

rs17079534

23007406

Mixed

chr3: 39847072

MYRIP

Sample population
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Reported gene
IKZF1, DDC

Table II continued…
Chromosome
nucleotide position

Reported gene

Mixed

chr2: 150457624

LOC642340

23007406

Mixed

chr18: 40591084

RIT2

rs7578361

23007406

Mixed

chr2: 150397218

Intergenic

SNP

PMID**

rs10170236

23007406

rs9958208

Sample population

rs7142143

23007406

Mixed

chr14: 51403531

PYGL

rs41322152

23007406

Mixed

chr10: 72040805

NPFFR1

rs6683977
rs546784

23007406
23007406

chr1: 66769100
chr1: 66762466

rs6964969

23512250

Mixed
Mixed
European, African
American, Hispanic

PDE4B
PDE4B
IKZF1,DDC,
GRB10

rs4982731

23512250

European, African
American, Hispanic

chr14: 23585333

CEBPE

rs10821936

23512250

European, African
American, Hispanic

chr10: 63723577

ARID5B

*

chr7: 50473251

Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European Bioinformatics
Institute), Junkins HA, Hall PN, Klemm AK, and Manolio TA. A Catalog of Published Genome-Wide
Association Studies. Available at: www.genome.gov/gwastudies. Accessed September 10, 2013.
**

PubMed identifier number

10

CHAPTER II
HYPOTHESIS AND SPECIFIC AIMS
The purpose of this dissertation project is to explore the correlations among
genetic polymorphisms, birth characteristics, and the risk of childhood ALL. It is known
that gender is a risk factor for childhood ALL, with males having greater risk, and
Hispanics have the highest risk of all ethnicities. We hypothesize that risk markers may
not be universal for both genders and across ethnicities. We aim to exploit this
differential to obtain etiologic clues for the development of childhood ALL. Another
focal point is to test the hypothesis that iron-regulatory gene (IRG) variants known to
elevate iron levels increase childhood ALL risk. Iron, which is necessary for cell division
and fetal growth, has been shown to increase birth weight and susceptibility to cancer
when found in excess. This research will seek correlations between genotypes (IRG
variants) and phenotypes (birth characteristics and leukemia) to determine whether
genotypes and their combinations associated with birth characteristics also modify the
risk for leukemia.
In order to test these hypotheses, the following specific aims will be explored:
Aim 1) to genotype previously reported childhood ALL risk markers to validate the casecontrol sample used in this project for the first time;
Aim 2) to genotype lymphoma risk markers, since lymphoma and ALL both stem from
lymphoid cells, for their correlations with childhood ALL risk and birth characteristics;
Aim 3) to genotype iron-regulatory gene polymorphisms, some known to increase iron
levels, for their correlations with childhood ALL risk and birth characteristics
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Aim 4) to examine effect modification by race/ethnicity and gender in childhood ALL by
stratified statistical analysis
Findings of this study may indicate that genetic risk markers are not universal for
both genders and across ethnicities, and may be an important consideration in future
genetic association studies. It will also provide evidence for or against the idea that iron
excess mediated by genetic variants contribute to childhood ALL risk. If our hypothesis
is confirmed, educating the public on lifestyle modifications for preventive measures
such as controlled iron supplementation during pregnancy and avoidance from excessive
consumption of iron-rich food could reduce the risk of leukemia in children.
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CHAPTER III
HEREDITARY HEMOCHROMATOSIS GENE (HFE) POLYMORPHISMS AND
ASSOCIATIONS WITH DISEASE SUSCEPTIBILITY
Abstract
The implication of excess iron in cancer and disease susceptibility has long been
recognized. The increase in oxidative stress due to an overload of the transition metal is
believed to be the reason for its harmful effects on the body. The hemochromatosis
(HFE) gene is known to be involved in iron regulation, and mutations to the gene can
have negative effects on certain health conditions. In this review, we discuss the role iron
has in the body, and examine what impact HFE gene polymorphisms have on disease
susceptibility, focusing on childhood leukemia. PubMed was searched using the
following key words: HFE or hemochromatosis gene with disease susceptibility,
polymorphisms, cancer, leukemia, variants, or disease association. The mechanisms
behind the disease associations are also explored.
Role of iron
Iron is a necessary element required for oxygen transport, DNA synthesis, and is
involved in cell proliferation and fetal growth [1-4]. Iron is capable of donating and
accepting an electron, converting from ferrous (Fe2+) to ferric (Fe3+), which makes it
useful in metabolic reactions, but also potentially harmful to the body. Iron generates free
radicals when abundant and not tightly bound, which can lead to cell damage.
In humans, iron is found in heme proteins and in ferritin, an iron storage protein
[5]. Iron is most commonly stored in the liver, spleen, and in bone marrow [6].
Circulating plasma iron is typically bound to one of the two binding sites on the protein
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transferrin (TF) in healthy individuals. Cellular uptake of iron is dependent on the
number of transferrin receptors (TFRCs) [5]. When cells are in need of iron, there is an
increase in transcription of TFRC, and it is found greater numbers, therefore more
receptors available for the TF-iron complex to bind and become internalized [5]. The
opposite occurs when intracellular iron levels are high, in that transcription of TFRC
mRNA is decreased, and therefore there are a reduced number of receptors available [5].
Intracellular iron is used for both ferritin and hemoglobin production, the protein found in
red blood cells responsible for carrying oxygen throughout the body.
Health issues may arise when either too little or too much iron is stored and
absorbed in the body. Iron deficiency, commonly referred to as iron anemia, has been
extensively researched and is a common condition. In individuals with iron anemia,
TFRC production is typically increased, while ferritin production is decreased. The lack
of iron can lead to a wide range of adverse health outcomes [7]. Iron overload has not
been studied as extensively until recently, and is underestimated and underdiagnosed by
physicians. The primary reasons behind iron overload include: 1) excessive intake of iron
through intestinal absorption, 2) parenteral iron (intravenously or intramuscular), 3)
inhaled iron, 4) release of stored iron into blood plasma, 5) the reduction of normal
menstrual excretion of iron in premenopausal women, and 6) the lack of transferrin or
lactoferrin protein [8]. When found in excess, iron can induce cell stress and oxidative
damage due to the increase in free radicals [3,9]. With the depletion of antioxidants,
DNA damage can progress cancer development or worsen symptoms of an inherited
disease [10]. The role of iron in cancer and disease progression has been widely studied
[9], yet the genetics behind iron overload is still not fully understood. The
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hemochromatosis gene (HFE) encodes for a protein involved in iron regulation, and its
mutations may increase the risk of developing numerous cancers.
HFE gene
The HFE (high iron FE) gene is located at 6p21.3, the short arm of chromosome 6
at position 21.3, and is surrounded by histone genes at both ends. The gene is
approximately 10kb in size, and has at least eleven alternative transcripts consisting of
four to seven exons, all which encode a distinct domain of the protein [11]. The gene
encodes for a 321 amino acid mature transmembrane protein product that is similar in
structure to HLA Class I molecules, with two alpha and beta chains, although it is not
involved in antigen presentation [11,12]. It was originally named HLA-H because of the
similarities with other HLA genes.
The HFE protein is expressed on cell surfaces in most tissues, but found most in
the liver and small intestine [11], where iron absorption, transport, and storage takes
place. HFE is also expressed on the apical plasma membrane of the syncytiotrophoblasts,
which suggests it is the protein which regulates iron transport from the mother to the
fetus [9]. Genome-wide association studies (GWAS) looking at hematological parameters
such as serum markers of iron status have found significant associations with SNPs in the
HFE gene. A list of the traits showing statistical significance with variants in the HFE
gene is found in Table I.
Although not clearly understood, the HFE protein is involved in iron homeostasis
regulation, controlling iron uptake by interacting with transferrin receptor (TFRC) and
hepcidin (HAMP) [13]. The main function of HFE is to regulate mucosal iron transfer in
interaction with TFRC, mainly in the intestinal mucosa (iron absorption) and in the
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placenta (materno-fetal iron transfer). Animal studies first discovered high levels of
saturated serum transferrin and excessive iron buildup in the liver in HFE-deficient mice
[14]. The high iron levels in the hepatocytes of HFE-deficient mice are similar in
histopathology to humans with hereditary hemochromatosis, suggesting that HFE is in
control of iron homeostasis [9]. Transferrin receptors allow iron intake into the cell when
iron concentrations are low by binding with iron-bound transferrin molecules. When iron
levels are adequate and pH conditions are neutral, the HFE protein binds to the TFRC
complex, reducing cellular iron uptake [12]. The hormone hepcidin is a negative
regulator of iron absorption that determines how much iron will be stored and released
[15]. HFE is speculated to regulate hepcidin by keeping production levels high when
there is enough iron inside the cell, ensuring that the body will not absorb or store too
much iron [15,16].
The interactions between HFE and TFRC have been observed previously in both
adult cancers [17] and in childhood acute lymphoblastic leukemia [18]. In the study
conducted by Beckman et al., variants of HFE and TFRC genes on their own were not
associated with breast, colorectal, or multiple myeloma, but their genotype combinations
were significantly different between controls and cases [17]. It is speculated that the
carcinogenic effect may somehow be amplified with the combination of both gene
variants, and be dependent on increased iron uptake [17]. Normal, wild-type HFE protein
is able to bind to transferrin receptors, reducing the affinity of TF, therefore controlling
iron homeostasis. When HFE is mutated with the C282Y mutation, this binding is unable
to occur, therefore allowing TF to bind to the receptors, and iron absorption to be
uncontrolled. Mutations to the HFE gene disrupt iron homeostasis by causing increased
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iron levels, which can lead to many negative health conditions, including hereditary
hemochromatosis (HH).
HFE variants
Since the discovery of the HFE gene in 1996, many single nucleotide
polymorphisms (SNPs) have been identified [19,20]. Information describing the most
popular SNPs can be found in Table II. The two originally discovered missense
mutations, rs1800562 (C282Y) and rs1799945 (H63D), account for most of the disease
associations with HFE.
C282Y is the result of a point mutation in the coding sequence (exon 4) of the
gene, with a guanine-to-adenine transition at nucleotide 845. This alters the production of
the amino acid in position 282, changing it from cysteine to tyrosine [21]. This mutation
is the most deleterious, as the cysteine residue is highly conserved, and the protein is no
longer able to bind properly to TFRC when altered. The transferrin molecule is then able
to bind to the TFRC with high affinity, and iron is released [22]. The frequency of C282Y
in the United States is estimated to be around 6% in non-Hispanic Whites [23]. The
C282Y mutation appeared more than 2000 years ago and is now associated with a
particular haplotype in European populations, and is not found or found in low allele
frequencies in other populations [24]. Two copies of the C282Y mutation is found in
approximately 90% of patients with hereditary hemochromatosis (HH), an autosomal
recessive disorder causing iron overload [25].
The second most common HH associated variant is the H63D mutation, which is
a result of guanine replacing cytosine at nucleotide 187, causing the amino acid in
position 63 to change from aspartate to histidine. This mutation only shows symptoms of
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iron overload when the individual also has a copy of the C282Y mutation on the other
chromosome, and symptoms are typically mild [25]. The variant protein is still able to
bind to TFRC, although it is unable to reduce the affinity of transferrin binding to the
receptors [26]. H63D mutations are more frequent than C282Y, with approximately 15%
of non-Hispanic Whites being carriers of the mutation in the US, and 3% having two
copies [23]. The penetrance of H63D is low, and the variant needs to be coupled with the
C282Y variant in order to have an effect on iron levels. However, C282Y and H63D can
never exist on the same chromosome.
A third mutation, rs1800730 (S65C), consists of an adenine to thymine
substitution at position 193, causing the amino acid serine to change to cysteine at
position 65 [27]. Studies have shown that this variant is associated with a mild form of
hemochromatosis [28], having a greater effect when found in the presence of other HFE
variants [29]. S65C is less common than C282Y and H63D, found in less than 5% of the
non-Hispanic White population [28].
The SNP rs807212 was identified as tagging for the most common HFE region
haplotype [30]. This intergenic SNP appears to tag for the wild-type alleles for all HFE
variants, meaning the haplotype lacked all disease-associated variants [30]. There was a
strong gender effect noticed with this SNP. Males had strong protective association
against childhood leukemia, which made biological sense as male carriers of the variant
rs807212 were therefore absent of the C282Y mutation, which had previously been
associated with childhood leukemia risk [30-32].
The transition substitution in intron 1 creates the HFE SNP rs9366637. This SNP
has been identified as a tagging SNP as well, but has not been studied extensively. It has
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not yet been implicated in iron regulation, however, the haplotype tagged by rs9366637
lacks C282Y and H63D. The minor allele frequency for this SNP varies greatly
depending on the race/ethnicity of the population, with the CEU (Western European
ancestry) T-allele frequency being 0.06 and the HCB (Han Chinese in Beijing, China)
having a MAF of 0.49. The variant (T) allele has been shown to be a marker of increased
birth weight in European childhood ALL patients [18]. In a case-control study in a Han
Chinese population, the C allele was found to be a significant risk marker for coronary
heart disease (CHD) [33]. In a meta-analyses study looking at HFE gene variants and
CHD in Han Chinese, only an association with rs1799945 variant allele increased risk for
CHD, and the association with rs9366637 did not reach overall statistical significance
[34]. The SNP was also found to be a marker for height in a GWAS [35].
Disease associations with HFE mutations
Hereditary hemochromatosis
Hemochromatosis describes any disorder caused by iron excess and tissue injury
[25]. Hereditary hemochromatosis (HH) is the most commonly inherited form of iron
overload. This autosomal recessive disorder may lead to severe organ dysfunction over
time because of high iron absorption [25]. It is estimated that 90% of those with HH who
are of northern European descent are homozygous for the C282Y mutation [36]. It is very
common in that particular population, affecting 1 in every 200-300 individuals [37]. The
condition is expressed more severely in males rather than females, as women are able to
reduce their iron levels through the loss of blood during menstruation and childbirth [38].
Homozygosity for the C282Y variant or heterozygosity of C282Y and H63D on
separate chromosomes are the two primary genetic combinations that cause HH [37].

19

When the C282Y mutations are present, the mutated HFE protein is no longer able to
interact with transferrin receptors and hepcidin on at the cell surface [37]. Low hepcidin
production is a result of the mutation, causing the cells to think iron levels are low and
absorption is necessary. The excessive storage occurs primary in the liver, heart, joints,
pancreas, skin, and testes [39]. Homozygosity of H63D on its own will not cause HH, but
with a C282Y mutation may [40]. Determining the penetrance of the disorder is difficult
to assess [41], as many patients do not show any signs or symptoms, particularly those
who are heterozygotes [37]. Even with those that do show symptoms, they take a long
time to develop, and clinical indicators are not apparent until at least middle age [31].
The horizontal bar chart depicted in Figure I represents the probability of developing HH
based on HFE genotype. The highest risk is among C282Y homozygotes, with risk
decreasing gradually for C282Y/H63D heterozygotes, H63D homozygotes, and C282Y
heterozygotes. Homozygosity for H63D has the same risk as individuals who are not
carriers of any HFE variants.
Once symptoms of iron excess develop, they can range from mild iron elevation
to severe heart and liver disease [37]. Early symptoms include weight loss, lethargy, and
stomach pain [39]. The liver is the first organ to typically show signs of HH, with
hepatomegaly developing frequently [38]. Approximately 10-15% of patients with
hepatocellular carcinoma have HH [38,42]. Other disorders that may stem from HH
include diabetes, cardiomyopathy, and hyperpigmentation [38].
Hereditary hemochromatosis can be diagnosed by checking transferrin-iron
saturation (TS) and serum ferritin concentrations. Serum transferrin-iron saturation
greater than 50% in women and 60% in men is common in individuals with HH [38]. It is
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not feasible to do prenatal testing for HH, since the disorder is treatable. The only way to
treat HH is by removing iron from the body. The easiest way to do this is through
phlebotomy. Individuals with HH should also monitor their iron intake, from both
mineral supplements and with food choices [5].
Disease associations
Iron excess has been implicated in many different cancers and diseases, described
in Table II. Studies have shown that iron can affect carcinogenesis by either suppressing
the hosts’ defense cells, acting as a nutrient for growing tumor cells, or by increasing
oxidative stress with an increase in free radicals [17]. Free radical generation leads to
inflammation and mutagenesis within the body [43]. Hereditary hemochromatosis is a
well-established model of iron-induced carcinogenesis [10].
Many HH patients develop cirrhosis of the liver, and are at an increased risk for
liver cancer. Primary hepatocellular carcinoma, in particular, is 200 times more common
in these patients [42]. The liver is the major site of iron storage, therefore liver disorders
are not surprising in HH patients. Increased risk for liver cancer has been seen not only in
HH patients, but also in non-HH individuals with iron overload [44,45]. HH patients are
also at an increased risk for diabetes [42]. The mechanism is not clearly understood, but it
is hypothesized that iron accumulation damages pancreatic beta cells and insulin
resistance [46]. Heart conditions such as cardiomyopathy and arrhythmias have been
observed in in high numbers of HH patients as well [38]. Studies have shown that
reducing iron stores through blood donation reduces the risk for heart disease [43].
Whether or not the C282Y mutation is a risk factor for developing heart disease is still
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debated. Factors including smoking and hypertension status in women with heart disease
may confound the association [47].
Many studies have explored the association between neurodegenerative disorders
association and iron accumulation in the brain [48]. Iron accumulation is consistently
observed in Alzheimer disease (AD) and its involvement in neuritic plaques has been
well documented [49]. AD is enhanced by oxidative stress, and excess free iron would
lead to oxidative stress through generation of free radicals in the neurons. Both C282Y
and H63D have been associated with an increased risk for Alzheimer [26,50-52].
HFE variants and childhood leukemia risk
Previous studies have examined the risk association between HFE mutations and
childhood acute lymphoblastic leukemia (ALL) risk [18,31,32,53,54]. The C282Y
mutation was reported to be a risk factor for male children in a case-control study of
Welsh and Scottish populations [53]. The minor allele frequencies for C282Y in males
was 23.4% in cases and 12.3% in controls for the Wales population, and 34.7% in cases
compared to 15.1% in controls in the Scotland group [53]. These populations are quite
homogenous; therefore the generalization of the findings is unknown. H63D did not show
any association with childhood ALL risk.
A Finnish study [55] is the only other published study that looked at HFE variants
in childhood leukemia. The study population only included 32 childhood ALL patients,
of which 14 were male, and did not find any significant results. Other hematologic
malignancies studies on acute myeloid leukemia [56] and Hodgkin disease [32] have
found no risk associations with HFE variants, and a myelodysplastic syndrome study [57]
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revealed a positive association, which was not been replicated in a different population
sample [58].
Mechanism
It is speculated that most cancer risk associated with increased iron levels is due
to iron accumulation over years, resulting in chronic oxidative stress. The association
with childhood leukemia cannot therefore be explained by this same reasoning.
Chitambar et al. have suggested that increased intracellular iron levels in lymphoid cells
during development may explain the risk [59]. Cell studies have shown that B-lymphoid
cell lines that are homozygous for the C282Y variant demonstrate greater iron uptake and
increased cell sensitivity to oxidative stress [59]. The increase in oxidative stress due to
the high iron levels may increase radiation sensitivity, which has been shown to increase
cancer susceptibility [60,61]. Lymphocytes can be radiation sensitized by iron, and
Stevens et al. have identified C282Y heterozygotes as risk factors for radiation sensitivity
[62,63]. Growing fetuses are sensitive to environmental insults, and those who are
carriers of the C282Y variant may be exposed to higher intracellular levels of iron,
especially if their mother is a carrier [31]. This hypothesis, of course, must be carried out
in functional studies to determine its validity.
Another idea is that the HFE gene may play a role with immune function [53].
Mutations in HFE causing iron overload may interfere with the immune function of
lymphoid cells, and be an underlying reason for the association with childhood leukemia
risk. The role of HFE with the histone proteins may also be important [30]. The HFE
gene is flanked by histone coding genes on both sides, and histones are known to be
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important in genome biology and potentially with tumor suppression [30]. There may be
similarities between the two or interactions between the genes that are unknown.

Conclusion
With well-known biology of its effects, iron excess is likely to have more impact
on cancer and neurodegenerative diseases in the Western world. Iron supplementation is
currently unregulated and non-personalized, with every male and female given the same
suggested amount to intake. Educating the public on lifestyle modifications for those with
iron overload such as controlled iron supplementation and avoidance from the
unnecessary consumption of iron-rich food, could reduce ill side effects from the
disorder. After decades of serological work trying to determine the effects of iron
accumulation in the body, genetic epidemiology has made more of an impact in a shorter
period of time.
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Table I. GWAS findings for HFE polymorphisms*
PMID**
19820699
19084217
21483845
23446634
20927387
20858683
19820697
21785125
21943158
19862010
23263863
20686565
21909115
21208937
19820698
20139978
21909110
19853236
21149283
21149283

Trait

SNP

Iron status biomarkers
Red blood cell traits
Glycated hemoglobin levels
Hematological parameters
Hepcidin levels
Cardiovascular disease risk factors
Hematocrit
Hemoglobin
Mean corpuscular volume
Hematology traits
Mean corpuscular hemoglobin
Cholesterol, total
LDL cholesterol
Diastolic blood pressure
Hypertension
Systolic blood pressure
Iron levels
Hemoglobin
Mean corpuscular volume
Blood pressure
Hematology traits
Iron status biomarkers
Iron status biomarkers

*

rs1800562

rs1799945

rs198846
rs1408272
rs17342717

Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European Bioinformatics
Institute), Junkins HA, Hall PN, Klemm AK, and Manolio TA. A Catalog of Published Genome-Wide
Association Studies. Available at: www.genome.gov/gwastudies. Accessed September 10, 2013.
**
PubMed identifier number
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Table II. Characteristics of most studied SNPs in the HFE gene
SNP

Nucleotide
position*

rs1800562

26093141

rs1799945

26091179

rs1800730

26091185

rs807212

26065621

rs9366637

26089098

rs2794719

26088890

rs2858996

26094026

rs2071303

26091336

rs1800708

26093303

rs1572982

26094367

*

Polymorphism type and
location
Coding; nonsynonymous;
substitution of cysteine (C)
by tyrosine (Y) at amino
acid position 282 (C282Y)
Coding; nonsynonymous;
substitution of histidine
(H) by aspartate (D) at
amino acid position 63
(H63D)
Transversion substitution
(S65C)
Transition substitution,
intergenic
Intronic, transition
substitution (IVS1)
Intron, transversion
substitution, intragenic
Transversion substitution,
intron/intragenic
Transition substitution,
intron, intragenic
Transition substitution,
intron, intragenic
Intron, transition
substitution, intragenic

Minor allele and frequency**
Sequence

CEU

YRI

JPT

HCB

ATATACGT(A):(G)CCAGGTGG

(A) 0.053

NA

NA

NA

TCTATGAT(C):(G)ATGAGAGT

(G) 0.179

(G) 0.00

(G) 0.042

(G) 0.125

ATCATGAG(A):(T)GTCGCCGT

(T) 0.033

NA

NA

NA

TTTTACCC(A):(G)GGAGTGGA

(A) 0.358

(A) 0.042

(A) 0.091

(A) 0.089

TTTGCATT(C):(T)TAGTGGGA

(T) 0.066

(T) 0.075

C 0.385

(T) 0.493

CAAAGCCC(C):(A)GTGTACCA

(C) 0.397

(C) 0.155

(A) 0.302

(A) 0.256

GAGTTTGC(T):(G)TAGCTATC

(T) 0.208

(T) 0.089

(T) 0.066

(T) 0.179

CTCTCCAC(A):(G)TACCCTTG

(G) 0.341

(G) 0.401

(A) 0.221

(A) 0.367

GGGTGGGC(C):(T)GAGGGTGG

(C) 0.080

(C) 0.088

(T) 0.319

(T) 0.456

GCAAGATG(A):(G)TGCCTAGG

(A) 0.456

(G) 0.312

(G) 0.159

(G) 0.296

Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/)
Population descriptors:
CEU (C): Utah residents with Northern and Western European ancestry from the CEPH collection
YRI (Y): Yoruban in Ibadan, Nigeria
JPT (J): Japanese in Tokyo, Japan
HCB (H): Han Chinese in Beijing, China

**
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Figure I. Likelihood of developing adverse health effects from hereditary
hemochromatosis based on HFE genotype
Adapted from: Khoury MJ, Burke W, Thomas EJ, editors. Genetics and Public Health in the 21st Cen
Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford Press; 2000.
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Table III. Conditions showing increased risk associations with HFE variants
Condition
Alzheimer disease

*

PMID*
12707938, 15060098, 11445256,
10861683, 20029940, 17119292

Amyotrophic lateral sclerosis

17828789

Arthritis

12401309, 17284543, 16468045,
16583477, 16638105

Breast cancer

10383894, 14973098, 20099304,
16216474, 16503999, 23681799

Cardiovascular disease

12401309, 21696736, 20640879,
17389307

Cervical cancer

16414021

Childhood acute lymphoblastic leukemia

19806355, 10627122

Colon Cancer

10383894, 12529348, 20099304,
19291797, 15941956, 23553028,
23281741

Diabetes

8613000, 9654270, 9726605, 9885759,
22908207

Gastric cancer

23389292

Glioma

11591868, 19386095

Hepatic veno-occlusive disease

15834437

Liver cancer

10845668, 10989544, 11500061,
12003382, 15929796, 15017669,
18164971, 23281741, 10918159,
12591066, 1312985, 4058506, 8613000

Neurodegenerative diseases

12401309, 23813494, 22526559,
21349849, 21346098

Ovarian cancer

20669231, 21879820

Prostate cancer

16003728

PubMed identifier number
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CHAPTER IV
GENETIC MARKERS IN A MULTI-ETHNIC SAMPLE FOR CHILDHOOD
ACUTE LYMPHOBLASTIC LEUKEMIA RISK
Abstract
Genome-wide association studies (GWAS) have identified multiple risk loci for
childhood acute lymphoblastic leukemia (ALL), but mostly in European/White
populations, even though Hispanics have a greater risk compared to the European/White
population. We re-examined selected SNPs of known associations with childhood ALL
and known HLA region lymphoma risk markers in a multi-ethnic population sample from
Houston, Texas consisting of 161 incident childhood ALL cases and 231 controls.
Significant associations were found in two ARID5B variants (rs7089424, ORallele=1.69,
P<0.001; and rs10821936, ORallele=1.48, P=0.005), as previously shown in GWAS.
Marker rs2395185, which is a protective marker for lymphoma, replicated the previously
found strong risk association with childhood ALL in non-Hispanic White males
(ORallele=2.79, P= 0.02), but no association was noted in Hispanics. Another HLA region
marker rs2647012 showed a statistically significant risk association among Hispanics, but
not in non-Hispanics (Pinteraction = 0.003 for ethnicity). A strong statistically significant
protective association was found with rs1048456, a risk marker in follicular lymphoma
(ORrec=0.19, P=0.009). Our study validated this new case-control sample by confirming
some of the previously discovered genetic markers associated to childhood ALL, and
yielded new associations with known lymphoma markers. The association of lymphoma
markers were in opposite direction in childhood ALL. Despite positive results, our study
did not provide any clues to why Hispanics have a higher susceptibility to childhood
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leukemia, suggesting that environmental factors may have a stronger contribution to this
differential.
Introduction
Over a third of cancers in children are leukemias [1], with acute lymphoblastic
leukemia (ALL) being the most common [2-4]. Approximately 3.8 individuals (less than
14 years of age) per 1,000,000 are diagnosed with childhood ALL per year in the United
States [5]. The racial disparity in the incidence of childhood ALL has been well
established [6,7]. In the United States, incidence of ALL is greatest in Hispanic children,
followed by non-Hispanic Whites, Asians, and then Blacks [7-9].
Research continually tries to determine the etiology of childhood leukemias.
While there are a few known risk factors associated with childhood ALL [10-15], more
than 90% are of unknown etiology [11]. Increased birth weight is an established risk
factor shown to increase risk of childhood ALL [16-33]. Environmental factors are also
involved, and may work in conjunction with genetic factors to cause many cancers [10].
Genome-wide association studies (GWAS) [34-37] have identified multiple risk
loci showing significant associations with childhood ALL. Most significantly, variants
located within the ARID5B, IKZF1, and CEBPE genes have robust risk associations.
Most of these studies, however, have only evaluated risk among those of European
ancestry. Two multiethnic studies conducted by Xu et al. looked at various risk loci in
both African American and Hispanic American populations [8,37], discovering that some
markers are universal across races/ethnicities, while others are race/ethnic-specific.
We re-examined five previously discovered single nucleotide polymorphisms
(SNPs) of known associations to leukemia (rs7089424, rs10821936, rs10994982,
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rs4132601, and rs2239633), along with three HLA region susceptibility markers for
lymphomas, since lymphoma and ALL both stem from lymphoid cells. These included
rs2395185, a marker of HLA DRB4 lineage [38] which has previously shown risk
associations with major leukemias including childhood ALL and other diseases [39-49];
rs10484561, which has been shown to be a strong risk marker in follicular lymphoma
(FL) [50]; and rs2647012, which is a protective marker for FL [51]. These SNPs were
examined in a multi-ethnic sample (non-Hispanic Whites, Hispanic Whites, and Blacks)
from Houston, Texas to assess their association with ALL. We hypothesized that the
variation in ethnic/racial susceptibility to childhood ALL has a genetic basis.
Subjects and Methods
Study population
Institutional Review Board (IRB) approval was received at both the Baylor
College of Medicine (BCM) and Florida International University prior to the start of the
study. The case-control study comprised of 161 incident childhood ALL cases and 231
healthy age-matched controls contemporaneously recruited at the Texas Children’s
Cancer Center, at BCM in Houston, TX from 2007 to 2012. The children were less than
18 years of age at diagnosis, and exclusion criteria for both cases and controls were
refusal to participate in the study and the diagnosis of any other disease or cancer.
Subjects or their parents provided informed consent for provision of epidemiological data
with a questionnaire and a biological sample. The DNA samples were extracted from
saliva or peripheral blood samples at BCM. Race/ethnicity was determined by the
responses provided on the questionnaire. Parents were requested to state the race (White,
Black/African American, Asian, American Indian/Alaska Native, or Native
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Hawaiian/Other Pacific Islander) and ethnicity (Hispanic/Latino or non-Hispanic/Latino)
of the child. The questionnaire also collected the race/ethnicity of the parents, which was
used to verify the response. Information on clinical subtype of ALL was collected from
medical records.
Genotyping
The main features for the SNPs genotyped are shown in Table I. Pre-developed
TaqMan® SNP Genotyping Assays (LifeTech, Foster City, CA) were used for all of the
SNPs we examined. Genotyping was achieved using the Bio-Rad CFX96 real-time PCR
machine (Hercules, CA). The TaqMan assays consist of singleplex reactions carried out
in ninety-six well plates. Each plate contained two no template controls (NTCs), a
positive control, and random replicate samples. Bio-Rad SsoFast™ Probes Supermix, a
2x reaction buffer which contains the necessary components for running the PCR; Sso7dfusion polymerase, dNTPs, MgCI2, and stabilizers, was used with the TaqMan Assay.
PCR amplifications were performed using the manufacturer’s suggestion of 20 µL total
volume and with the following PCR thermal cycling conditions: enzyme activation at
95oC for two minutes, and 49 cycles of denaturation at 95oC for 5 seconds followed by
annealing and extension at 61oC for 5 seconds. Bio-Rad CFX Manager software (version
3.0) was used for data acquisition and genotype assignment.
Statistical analysis
Statistical analyses were performed using Stata v.11 (StataCorp, College Station,
TX). Pearson’s Χ2, Student's t-test (for means) or median test (for medians) were used to
compare characteristics between the cases and controls. Logistic regression methods were
used to calculate crude and adjusted odds ratios (OR) and 95% confidence intervals (CIs).
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All statistical tests were two-tailed, and the threshold for statistical significance was set at
P≤0.05. The ORs, with 95% CIs, were used as a measure of effect size. Genotype counts
were tested for Hardy–Weinberg equilibrium (HWE) in controls for each SNP. By
default, we used the additive genetic model to assess associations by Cochrane-Armitage
trend test. Due to its previous association being in the recessive model, rs2395185 was
analyzed also for the recessive model association. Ethnic- and gender-specific
associations were calculated through stratified analyses. None of the SNPs were located
in coding regions, therefore we used RegulomeDB (Stanford University, Palo Alto, CA)
to calculate a score for regulatory function. To adjust for heterogeneity in our sample,
especially in Hispanics, we used two ancestry-informative markers, AIMs, to control for
confounding caused by population stratification and to avoid spurious associations [52].
The two AIMs we used, rs285 and rs2891, have been previously used in Hispanic
populations to account for the differences in genetic ancestry [53,54]. The risk
associations were adjusted by each of the AIMS.
Results
All cases and controls were genotyped for the eight candidate SNPs and two
ancestry-informative markers (AIMs). Genotype call rates were greater than 95% for both
cases and controls. Table II shows characteristics of the case-control sample. The case
samples included 86 males (53%) and 75 females (47%). Out of these cases, 66 identified
themselves as non-Hispanic White, 72 as Hispanic White, 17 as Black, and 6 as “other.”
The group labeled “other” included those identifying themselves as Asian, Native
American, or other. The healthy controls included 130 males (56%) and 101 females
(44%), who had visited the pediatric clinic at BCM for a non-disease related reason.
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Forty-nine were classified as non-Hispanic White, 98 as Hispanic White, and 78 as
Black. The distribution of ethnic background was different between cases and controls
mainly due to the infrequency of childhood ALL. Because of this difference, results were
adjusted for ethnic background or stratified analyses were performed when necessary.
There was no significant difference in the means between the case/control groups in
regards to birth weight. Birth length and gestational age did not differ between cases and
controls, except in specific subgroups. There was a significant difference in gestational
age between cases and controls, only in the Hispanic female subgroup. The difference in
birth length means was significant, but only in the non-Hispanic White subgroup. Eightyeight percent of the cases were diagnosed with early precursor B (early pre-B) ALL
subtype, and associations did not change in effect size depending on the molecular
subtype. There were no significant genotype associations found within the Black
subpopulation, possibly due to the small number of cases in the population sample.
GWAS risk markers
Results including genotype frequencies and odds ratios are described in Tables
III-V. Analyses yielded significant associations with some of the genetic markers similar
to previous reports. In total, three ARID5B SNPs were examined for associations. Two of
the ARID5B SNPs, rs7089424 and rs10821936, showed expected risk associations, while
rs10994982 did not show an association (Table III). The SNP rs7089424 had an overall
odds ratio per allele (ORallele) of 1.69 (P>0.001). The association showed a somewhat
stronger risk in the non-Hispanic subgroup (ORallele=2.11, P=0.01), compared with
Hispanics (ORallele=1.61, P=0.02). Similarly, rs10821936 had an overall ORallele=1.48
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(P=0.05). Adjustments of the analyses for race/ethnicity did not change the observed
results. Adjustment for AIMs did not appreciably alter the results either.
There were no significant associations found for IKZF1 rs4132601 or for CEBPE
rs2239633. Hardy-Weinberg equilibrium was violated in controls for rs4132601, which
could lead to spurious results, and was therefore excluded.
HLA region lymphoma risk markers
The SNP located in the HLA-DR region, rs2395185, showed a weak, nonsignificant risk overall (Table IV). This SNP is an exclusive marker for the HLA-DRB4
(DR53) lineage [38]. Since this lineage was shown to be a risk marker for childhood
ALL, but only in males [46], we examined rs2395185 association in males. The nonHispanic White male group had an ORallele of 2.79 (P=0.016). Figure I depicts the
childhood ALL risk in rs2395185 subgroup analysis, focusing on males and non-Hispanic
White males, specifically. The OR reached 6.21 (95% CI=0.70-54.96) for homoyzgosity
for the variant allele, which corresponds to the original association [46]. The known
protective marker for follicular lymphoma, rs2647012, showed a statistically significant
association in Hispanics ORallele =2.21 (P=0.007), but not in non-Hispanics (Pinteraction =
0.003 for ethnicity), as shown in Figure II. The significance remained after adjusting for
both rs23951885 and rs10484561. The variant rs10484561 was shown to be a strong
protective marker in this study, opposite of what was found in follicular lymphoma [50].
Using the recessive model, the variant allele showed a strong association, ORrec=0.19
(P=0.009). The two AIMs used, rs285 and rs2891, did not show any association as
expected (Table V).
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Discussion
Despite being well established, the racial disparity in the incidence of childhood
ALL is not always addressed in genetic association studies. Most GWAS, until recently,
have identified risk loci using only European-origin populations. Variant polymorphisms
located within the ARID5B, IKZF1, and CEBPE genes have reported strong risk
associations in multiple GWAS [34-37,55-57]. Our study provides some confirmation of
previously discovered genetic markers associated with childhood ALL, which also
validated our case-control set for further exploration.
Of the three ARID5B SNPs, rs7089424 and rs10821936 showed significant risk
associations, and rs10994982 did not show any associations. The ARID5B gene is
involved in transcriptional regulation with embryonic development [55]. Overexpression
of the gene in particular acute leukemias have led some to speculate that variations within
the gene may affect B-lineage development, and increase susceptibility to B-lineage
leukemia [35]. The marker rs7089424 was associated with a stronger risk of leukemia in
the non-Hispanic subgroup compared with Hispanics, replicating recent findings from
case-control studies using Hispanic populations [8,37].
In the recent multi-ethnic GWAS by Xu et al., rs10821936 was found to be a
significant risk marker across all ethnicities. Xu et al. noted that the risk allele
frequencies for rs10821936 increased in order by race incident rates: Black/African
Americans, non-Hispanic/European American, and Hispanic Americans [37]. Our results
showed a similar trend with an increasing risk allele frequency (RAF) in cases of Blacks,
non-Hispanic Whites and Hispanics. The multi-ethnic GWAS reported that rs10821936
was highly correlated with Native American genetic ancestry [37], substantiating their
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previous observations that Native American ancestry correlates with higher risk of
relapse in Hispanics, and leading to speculation that this may be a factor with the
increased risk for Hispanic children who have a high proportion of Native American
ancestry [58].
The SNP rs4132601, located in the Ikaros family zinc finger 1 (IKZF1) gene, is
associated with increased risk of childhood ALL in multiple studies [34,36,56,57,59].
The Ikaros proteins are known to be involved with lymphocyte development and
differentiation [34], and deletions are frequent and associated with unfavorable prognosis
in B-cell precursor ALL [34, 60]. One study found this variant to be a significant risk
marker amongst non-Hispanic Whites, but not in Hispanics, despite similar allele
frequencies [57]. Chokkalingam et al. hypothesized that that this marker’s association
may be due to linkage disequilibrium with a functional variant, and because of admixture
in Hispanic populations the linkage disequilibrium may vary [57]. Our study was unable
to examine this SNP, due to Hardy-Weinberg disequilibrium found in controls, even after
stratification for race/ethnicity.
The present study confirmed some, but not all previous findings of GWAS. With
the ARID5B risk SNPs, there was heterogeneity even between the first two GWAS
reports [34,35]. The modest sample size we had also reduced the statistical power of our
study. Nevertheless, confirmed results validated the present case-control sample for
further genetic association studies.
The relevance of lymphoma-associated polymorphisms in childhood ALL was
assessed by genotyping rs2395185, rs10484561, and rs2647012. The SNP near the HLADRA gene, rs2395185, is a marker for the HLA-DRB4 (DR53) lineage [38]. The HLA-
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DRB4 lineage or its marker SNP have been previously shown as a risk marker in lung
cancer [39], asthma [40], rheumatoid arthritis [49], type I diabetes [48], adult acute
myeloblastic leukemia [61], chronic myeloid leukemia [62], chronic lymphoid leukemia
[63-65] and in childhood ALL (males only) [46,66,67], and as a protective marker for
non-Hodgkin lymphoma [41], and ulcerative colitis [42-44,47]. The DRB4/DR53 lineage
has been shown previously to have a risk association with childhood ALL, with male
specificity, within a European sample via HLA typing [46]. The first GWAS association
of rs2395185 was with ulcerative colitis [42,47]. The variant allele, T, was later found to
be a protective marker in a GWAS examining risk factors for classical Hodgkin
lymphoma [41], and most recently a risk marker factor in Asian females for lung cancer
[39]. Our results replicated the strong male specificity of the risk for childhood ALL,
specifically in non-Hispanic White males, with no association in Hispanics. The DRB4
lineage has unique features, such as lower expression levels of HLA-DR molecules, poor
interaction with CD4, disrupted intracellular transport, and possibly contains extra
amount of DNA in the DR/DQ region which may contribute to this risk association in
childhood ALL [45]. One important finding of the present study is that the risk modifiers
of lymphoma showed opposite associations in childhood ALL.
The variant rs2647012, a marker for DRB3/DRB5 lineages and a protective
marker for lymphoma, showed a statistically significant risk association among
Hispanics, but not in non-Hispanics (Pinteraction = 0.003 for ethnicity). Our study appears to
be the first looking at a Hispanic population with this SNP, and further studies are
warranted to determine if this inverse relationship of risk exists in non-Hispanic and
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Hispanic Whites. Variant rs10484561 showed signs of being a protective marker for
childhood ALL, opposite to the follicular lymphoma findings [50].
It is now customary that the additive model is used to assess statistical
associations of SNPs. While the additive model has sufficient power to detect
associations in most situations, there are certain scenarios that it may not show statistical
significance when in fact, there is an association. An association conforming to the
strictly recessive model when allele frequency is low is one example [68-70]. For this
reason, and also because the original rs2395185 association was a recessive model
association, we also assessed this genetic model in HLA region associations. This
approach consistently yielded larger effect sizes for HLA region SNPs, especially for
rs2395185 as in previous studies. We are in favor of routine use of the recessive model
analysis in exploration of associations in the HLA region.
There are limitations of our study. With childhood ALL being a rare disease, the
sample size for our study was small, resulting in limited statistical power. The issue of
self-reported ethnicity may also be of concern. This method is common with populationbased association studies, and residual confounding is often suspected. Even though it has
been described that self-reported ethnicity may be reliable [71], the heterogeneity within
the Hispanic population is still a concern. A recent study conducted in a Spanish
population was unable to replicate original risk associations found in Hispanic
Americans, demonstrating the large heterogeneity in this high risk group [37,72].
To adjust for heterogeneity in our sample, especially in Hispanics, we used two
ancestry-informative markers, AIMs, to control for confounding caused by population
stratification and to avoid spurious associations [52]. The AIMs have widely different
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allele frequencies in major human continental groups. The two AIMs we used, rs285 and
rs2891, have been previously used in Hispanic populations to account for the differences
in genetic ancestry [53,54]. Adjusting the risk associations by AIMs did not alter the
results.
Our study did have a well-defined phenotype, with molecular ALL types
determined. The use of a multi-ethnic sample population was a strength, especially for
the ethnic disparity that persists with childhood ALL. Another strength is the use of
multiple genetic models, where appropriate, to determine associations that may remain
undetectable by the exclusive use of the additive model association. The replication of
known leukemia markers validated our sample set for further studies. This pilot study is
part of an ongoing effort at BCM. Recruitment for the second phase is continuing
together with clinical follow-up.
In summary, we validated a new multi-ethnic case-control set and also examined
some new markers with their association with childhood ALL. The examination of
lymphoma risk markers yielded associations in opposite directions for childhood ALL,
but also confirmed a previously identified childhood ALL risk marker. Two HLA region
associations were ethnicity-specific. Still, our study did not provide clues as to why
Hispanics have a higher susceptibility to childhood ALL, suggesting that environmental
factors may play a stronger role in this differential. Studies with information on
environmental exposures may help explain how gene-environment interactions contribute
to childhood ALL susceptibility and its variation among different populations.
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Table I. Main features of SNPs analyzed
SNP

Chromosome
nucleotide position*

ARID5B

rs7089424

chr10: 63752159

GWAS identified risk
loci for childhood ALL

ARID5B

rs10821936

chr10: 63723577

GWAS identified risk
loci for childhood ALL

ARID5B

rs10994982

chr10: 63710104

IKZF1

rs4132601

chr7: 50470604

CEBPE

rs2239633

chr14: 23589057

HLA-DR
region

rs2395185

chr6: 32433167

HLA-DQB1
region

rs2647012

chr6: 32664458

HLA-DQA1
region

rs10484561

chr6: 32665420

Gene

Minor allele
and frequency†

Location

RegulomeDB
score††

(G) 0.314

Intronic

3a

(C) 0.318

Intronic

5

19684603, 22660188

(A) 0.457

Intronic

NA

19684604, 22660188,
20054350

(G) 0.306

3'-UTR

5

19684604, 22660188

(A) 0.466

5'upstream

4

10397736, 12008082,
22286212, 7909466

(T) 0.423

Intronic

6

21533074, 22911334,
23455380

(T) 0.381

Intergenic

6

20639881, 21533074,
23025665

(G) 0.084

Intergenic

6

PMID**

Inclusion criteria

GWAS identified risk
loci for childhood ALL
GWAS identified risk
loci for childhood ALL
GWAS identified risk
loci for childhood ALL
HLA-DRB4/DR53
lineage; ALL risk
marker (in European
males); Hodgkin
lymphoma risk marker
HLA-DRB3/DRB5
lineage, protective
marker for non-Hodgkin
(follicular) lymphoma
HLA-DR1/DR10
lineage, risk marker in
follicular lymphoma

*

19684604, 22660188,
20042726
19684603, 20054350,
22660188, 23512250,
22291082

Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/)
PubMed identifier number
†
Minor allele frequencies are from a reference Caucasian population (U.S. residents of northern and western European ancestry) genotyped in HapMap
project
††
RegulomeDB scores range from 1 (most functional) to 5 (least functional) (6=other). Not all SNPs have a RegulomeDB score
(http://regulome.stanford.edu/)
**
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Table II. Characteristics of cases and controls
Cases

Controls

n=161

n=231

Non-Hispanic White

66

49

Hispanic White

72

98

Black

17

78

Other*

6

6

Male

86

130

Female

75

101

1.15

1.29

3349.3 (584)

3263.3 (684)

0.23

3400 (760)

3311.5 (850)

0.48

Gestational age (weeks) (SD)

38.8 (2.2)

38.2 (2.8)

0.04

Birth length (cm) (SD)

51.4 (3.4)

50.1 (5.05)

0.024

P value

Ethnic background
<0.001

Gender

Ratio

0.58

Birth weight (grams)
Mean (SD)
Median (IQR)

*

Other includes Asian, Native American, or other
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Table III. SNP associations previously shown as ALL risk markers in GWAS (overall*)
Case Subjects

Control Subjects

Minor Allele Frequency

Gene

SNP

Minor
Allele

A/A

A/B

B/B

A/A

A/B

B/B

Case

Control

ORallele**(95% CI)

P value

ARID5B

rs7089424

G

37

80

43

113

68

46

0.52

0.35

1.69 (1.28-2.24)

<0.001

ARID5B

rs10821936

C

39

72

44

104

69

50

0.52

0.38

1.48 (1.12-1.95)

0.005

ARID5B

rs10994982

A

55

78

25

90

78

43

0.41

0.39

1.00 (0.75-1.34)

0.992

IKZF1

rs4132601

G

76

68

16

141

56

29

0.31

0.25

1.19 (0.88-1.60)

0.269†

CEBPE

rs2239633

A

68

68

23

118

74

36

0.36

0.32

1.02 (0.76-1.36)

0.881

*

ORs adjusted for self-reported ethnicity and race

**
†

OR per allele (ORallele) for the additive model

Hardy-Weinberg disequilibrium in controls (overall and after stratification) for race/ethnicity
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Table IV. Association of HLA region lymphoma susceptibility markers (overall*)
Case Subjects

Control Subjects

Minor allele
frequency

SNP

Gene

Minor
allele

rs2395185

HLA-DR
region

T

69

68

22

120

72

25

0.35

0.28

rs2647012

HLA-DQB1
region

A

78

64

16

116

47

30

0.3

0.28

rs10484561

HLA-DQA1
region

G

128

23

3

149

21

18

0.09

0.15

*

A/B

B/B

A/A

A/B

B/B

Case

Control

ORs adjusted for self-reported ethnicity and race

**
†

A/A

OR per allele (ORallele) for the additive model;

OR recessive (ORrec) for the variant homozygous genotype

††

ORallele=1.88 (P=0.003) in males; ORallele=2.79 (P=0.016) in non-Hispanic White males
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ORallele**
(95% CI)
1.27
(0.94-1.71)
1.09
(0.80-1.47)
0.70
(0.46-1.06)

P value

0.127

0.595

0.094

ORrec†
(95% CI)
1.1
(0.65-2.26)††
0.57
(0.30-1.12)
0.19
(0.05-0.66)

P value

0.553

0.103

0.009

Table V. Ancestry-informative marker SNPs*
Case Subjects

Control Subjects

Minor allele
frequency

SNP

Gene

Chromosome
nucleotide
position**

Minor
allele

A/A

A/B

B/B

A/A

A/B

B/B

Case

Control

ORallele (95% CI)

P value

rs285

LPL

chr8:
19815189

C

43

68

48

92

61

53

0.52

0.41

1.26 (0.95-1.65)

0.103

rs2891

ITGAE

chr17:
3705526

C

56

66

37

114

72

42

0.44

0.34

1.14 (0.86-1.52)

0.362

*

ORs adjusted for self-reported ethnicity and race

**

Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/)
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Odds Ratio and 95% CI

6

OR=2.79
P=0.02

5
4
3

OR=1.88
P=0.003
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Figure I: Childhood ALL risk in rs2395185 subgroup analysis
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4

OR=2.21
P=0.007

Odds Ratio and 95% CI

3.5
3

P

interaction

2.5
2

OR=1.09
P=0.59

1.5
1
0.5
0

0

0.5

= 0.003 for ethnicity

OR=0.72
P=0.19

1

1.5

Overall

2

2.5
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Figure II: Childhood ALL risk in rs2647012 subgroup analysis
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CHAPTER V
EXAMINATION OF HFE ASSOCIATIONS WITH CHILDHOOD LEUKEMIA
RISK AND EXTENSION TO OTHER IRON REGULATORY GENES
Abstract
Hereditary hemochromatosis (HFE) variants that correlate with body iron levels
also show associations with cancer risk, including childhood acute lymphoblastic
leukemia (ALL). Two previous studies reported HFE associations with different gender
effects, but this association has not been evaluated in a US-based population. Using a
multi-ethnic sample of cases (n=161) and controls (n=231) from Houston, TX, we
examined two HFE variants (rs1800562/C282Y and rs1799945/H63D), one transferrin
receptor gene (TFRC) variant (rs3817672/S142G) and three additional iron-regulatory
gene (IRG) variants (SLC11A2 rs422982; TMPRSS6 rs855791 and rs733655) for their
associations with childhood ALL. Being positive for either of the two HFE variants
(C282Y or H63D) yielded only a modestly elevated odds ratio (OR) for childhood ALL
risk in males (1.40, 95% CI = 0.83 to 2.35), which increased to 2.96 (95% CI = 1.29 to
6.80; P = 0.01) in the presence of a particular TFRC genotype for rs3817672 (Pinteraction=
0.04). These findings were similar to the results reported in previous childhood ALL
studies. The TFRC genotype also showed an ethnicity-specific association, with increased
risk observed in non-Hispanic Whites (OR = 2.54, 95% CI = 1.05 to 6.12; P = 0.04;
Pinteraction with ethnicity = 0.02). Further support to the hypothesis that elevated iron levels
contribute to leukemia risk came from the three additional IRG SNPs. They all showed
individual risk associations with childhood ALL in males (OR = 1.52 to 2.60). A
polygenic model based on the number of variant alleles in these five IRG SNPs revealed
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a linear increase in risk among males with the increasing number of variants possessed
(OR = 2.00 per incremental change, 95% CI = 1.29 to 3.12; P = 0.002). Having three or
more variants in five IRGs was associated with increased risk (OR = 4.12; P = 0.004)
compared with having none, while corresponding OR in females was 1.22 (P = 0.71).
Our results replicated previous HFE risk associations with childhood ALL in a US
population and also demonstrated novel associations for IRG SNPs, thereby
strengthening the hypothesis that iron excess mediated by genetic variants contribute to
childhood ALL risk.
Introduction
The hereditary hemochromatosis gene, HFE, has shown multiple associations
with cancer susceptibility [1-7], including risk childhood acute lymphoblastic leukemia
(ALL) [8], which has been replicated in one other study [9]. In multiple cancers [1],
including childhood ALL [9], the association of HFE variants with cancer risk gets
stronger in interaction with a polymorphism in the transferrin receptor gene (TFRC).
Since HFE and TFRC proteins biologically interact in iron transfer across membranes
such as intestinal mucosa and placenta, this interaction supports the notion that the
involvement of HFE variants in cancer risk modification is mediated via their effect on
body iron levels [10]. Body iron levels have long been known to be positively correlated
with cancer risk as several cohort studies have shown [11-14], and iron’s carcinogenic
effect has been well documented [15]. Thus, HFE associations with cancer have strong
biological plausibility.
Recent genome-wide association studies (GWAS) have identified the HFE variant
C282Y as a major determinant of body iron levels [10]. The mediation of iron
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homeostasis by genetic variants extends beyond the HFE gene, with the strongest
association being TMPRSS6 rs855791 [16]. We reasoned that if HFE associations are due
to their effect on iron levels, other iron regulatory gene (IRG) polymorphisms should
show similar associations with childhood ALL risk. We therefore aimed to extend our
study beyond HFE variants to other IRG polymorphisms. To further test our hypothesis
that HFE variants modify the risk for childhood ALL via their effects on iron levels, we
also included the TFRC polymorphism that is known to interact with HFE variants in the
genotyping scheme to test whether this interaction raises the risk of childhood ALL. The
other IRG do not interact with TFRC biologically, so we did not predict any other
interaction. To test our hypothesis, we used a new case-control set, which was first
validated by replicating known childhood ALL associations.
Subjects & Methods
Subjects
Institutional Review Boards of Baylor College of Medicine and Florida
International University approved the study protocol. The case-control sample was from
Houston, TX, consisting of 161 incident cases with childhood ALL diagnosed at Texas
Children’s Hospital from 2007 to 2012, and 231 age-matched healthy controls
contemporaneously recruited. The children were less than 18 years of age at diagnosis,
and exclusion criteria for both cases and controls were refusal to participate in the study
and the diagnosis of any other disease or cancer. Subjects and their parents were
approached to obtain informed consent for provision of epidemiological data with a
questionnaire and a biological sample. The DNA samples were extracted from saliva or
peripheral blood samples at BCM. The sample was multiethnic to allow us to examine
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effect modification of childhood ALL risk by race and ethnicity (Table I). Race/ethnicity
was determined by the responses provided on the questionnaire by the children’s parents.
Our main interest was the contrast between non-Hispanic Whites (NHW) and Hispanic
Whites (HW), since childhood ALL is very rare in Blacks, and we had a very small
number of Blacks in the case group.
SNP selection
We included two HFE variants known to influence body iron levels commonly
known as C282Y (rs1800562) and H63D (rs1799945), as well as the TFRC variant
S142G (rs3817672), which is known to interact with HFE variants in previously reported
cancer associations. As other IRG variants, we included the GWAS-identified ironrelated SNP TMPRSS6 rs855791 [16], as well as two additional SNPs we selected also
from the TMPRSS6 gene (rs733655) and the SLC11A2 gene (rs422982) involved in the
non-transferrin receptor-related iron transfer across membranes. These two SNPs were
selected as the promoter region haplotype tagging SNPs for these two genes. The selected
SNP from TMPRSS6 is 32kb away and not in linkage disequilibrium with the GWASidentified marker in the same gene according to the HapMap project European population
data (r2 = 0.286). Two more SNPs were included as ancestry-informative markers (AIMs)
to adjust for the racial/ethnic heterogeneity in the multiethnic sample to supplement the
self-reported race/ethnicity data. The two SNPs were rs285 and rs2891, which were
identified as AIMs in previous studies due to their largely different allele frequencies in
major ancestral human populations [17,18]. Characteristics of each SNP are given in
Table II.
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Genotyping
TaqMan allelic discrimination assay was the choice of method for genotyping. All
SNPs were genotyped by TaqMan assays purchased from Life Technologies (Foster City,
CA) on the Bio-Rad CFX96 real-time PCR instrument (Bio-Rad, Hercules, CA). The
assay ID of each assay is given in Table II.
Statistical analysis
Genetic associations (both crude and adjusted) were evaluated by logistic
regression using Stata v.11 (StataCorp, College Station, TX). Statistical interactions were
also analyzed by logistic regression. All statistical tests were two-tailed and threshold for
statistical significance was set at P≤0.05. All genetic associations, except the TFRC locus,
were assessed by using the dominant genetic model which corresponds to variant allele
positivity and coded as 1 for heterozygote and variant allele homozygote genotypes, and
0 for the common allele homozygosity (referent). Due to the low frequency of their
variant alleles, the two HFE SNPs were pooled together by creating a new variable for
the number of cumulative variant alleles at both SNPs (0 for no variant allele, 1 for
variant allele at either SNP, 2 for heterozygosity at both SNPs or variant allele
homozygosity at either SNP (compound heterozygosity)). To be consistent with the
previous studies, TFRC SNP was analyzed in recessive model (by coding variant allele
homozygosity as 1 and the other genotypes as 0). A similar approach was used for a
polygenic risk model using the total number of variant alleles at all five IRGs (0 for no
variant allele at any SNP, 1 for one or two variant alleles at any SNP, 2 for three or more
variant alleles at any of the five SNPs). All statistical associations in the overall group
were adjusted for the race/ethnicity variable which had four categories (NHW, HW,
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Blacks, and others). The efficiency of adjustment for race/ethnicity was double-checked
by adjustment for each of the AIMs separately. Before proceeding to the statistical
analysis of genetic associations, Hardy-Weinberg disequilibrium was ruled out in
controls as a test for genotyping error.
Results
HFE C282Y and H63D frequencies in the sample population
As expected, the HFE C282Y mutation was more common in the NHW subjects:
variant allele frequencies were 0.113, 0.030 and 0.011 in NHWs, HWs, and Blacks,
respectively. The H63D variant positivity also had similar variation across race groups
with frequencies of 0.254, 0.151 and 0.032 in NHWs, HWs, and Blacks, respectively.
Only two cases and two controls (all NHWs) were compound heterozygotes for HFE
variants C282Y and H63D.
Univariable genetic markers analyses
Genotype frequencies for each SNP were in Hardy-Weinberg equilibrium in the
control group when analyzed for each race/ethnicity group. All associations reported
below for the whole group were adjusted for self-reported race/ethnicity. Replacing the
race/ethnicity variable by either AIM did not appreciably alter the results. As shown in
Table III, neither C282Y nor H63D showed an overall association with childhood ALL
risk. The TFRC SNP, which was included in the study to assess its interaction with HFE
SNPs did not show any individual association in the overall group. The two IRG variants
selected as haplotype tagging SNPs for the respective promoter regions showed
statistically significant associations in the overall analysis, but the association by the
GWAS-identified marker for the iron levels did not reach statistical significance in the
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overall analysis (Table III). This SNP only showed an association in males, as described
below.
Gender- and race/ethnicity-specific analyses and statistical interactions
The differences in risk between genders were not significantly different, as judged
by the statistical interaction test, but for the two TMPRSS6 SNPs, males had statistically
significant risk associations (Table IV). Despite yielding greater ORs for males, the malespecific HFE associations did not reach statistical significance in individual analysis.
Results from pooling of the two HFE variants in one variable (as described in the
methods) are shown in Figure I. The bars depict the risk genotype frequencies in the case
and control groups, and ORs for childhood ALL risk are provided. The risk did not yield
a statistically significant association in the overall group (OR = 1.46, P=0.17)(Graph A
in Figure I), but the pooled variable was associated with a significant risk in males (OR =
2.09, P = 0.04)(Graph B in Figure I), and even stronger when interacting with the TFRC
variant (OR = 4.92, P = 0.002)(Graph D in Figure I). Graph C depicts the frequencies
and OR for females cases/controls, and Graph E shows the frequencies and OR for males
with the wild type allele for TFRC.
There was no ethnicity-specific association of HFE variants. Ethnicity/racespecific analyses revealed a strong risk association (OR = 2.54, CI: 1.05-6.12, P value =
0.04) of the TFRC rs3817672 allele A homozygote genotype in NHWs, while the OR was
less than 1.0 (non-significant) in Hispanics. The interaction of ethnicity and this TFRC
genotype was statistically significant (Pinteraction = 0.02 for ethnicity). Thus, the only truly
ethnicity-specific association with childhood ALL was the NHW-specific association of
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TFRC. The strong association of the TMPRSS6 promoter region tagging SNP rs733655
was equally strong in both major ethnicities examined in this study.
We examined the TFRC and HFE gene-gene interactions previously observed in
multiple cancers [1], including childhood ALL. In the overall sample, there was no
interaction (data not shown). Our main group of interest was males because of the
previous findings in childhood ALL, and also because of generally higher ORs in males
in univariable analysis of HFE variants. Since the small sample size would not allow a
reliable assessment of interactions for rare HFE variants, especially C282Y, we used the
HFE pooled variant variable for this analysis. In the two groups of males with and
without the TFRC homozygous genotypes, the ORs were 0.59 (CI = 0.24 to 1.45) and
2.96 (CI = 1.29 to 6.80), yielding a statistically significant interaction (Pinteraction = 0.04).
We also examined interactions of non-HFE SNPs with TFRC. This analysis did not
reveal any interaction (P = 0.33, 0.46, and 0.96).
Polygenic risk model
We constructed a polygenic risk variable consisting of five IRG SNPs as
described in the Methods section. Analysis using this variable showed that for stepwise
increase in the number of variant alleles, there was a linear increase in childhood ALL
risk in the overall group (OR = 1.63, 95% CI = 1.18 to 2.26, P = 0.003)(Figure II), and in
males (OR = 2.00, 95% CI = 1.29 to 3.12, P = 0.002)(Figure II), but not in females (OR =
1.26, 95% CI = 0.77 to 2.08, P = 0.36) in stratified analyses. In ethnicity-specific
analysis, the association remained statistically significant in NHW (OR = 2.19, 95% CI =
1.18 to 4.06, P = 0.01), but not in Hispanics (OR = 1.42, 95% CI = 0.89 to 2.27, P =
0.14).
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Discussion
We examined previously reported HFE associations and interactions with TFRC
with the risk of childhood ALL. In this multi-ethnic sample, we observed associations
similar to previously reported ones with the same gender effect, and extended the
observations to other iron regulatory gene polymorphisms to provide further support for
our hypothesis that HFE and TFRC association in childhood ALL is due to their effect on
iron homeostasis. The only statistically significant gender-specific associations with IRG
variants and childhood ALL risk were in males, and we also noted a novel ethnicityspecific association with the TFRC variant.
Due to the limited sample size, we pooled the two HFE variants to increase
statistical power to detect their associations with childhood ALL. The ORs for the pooled
variables were always in the risk direction for individual SNPs, and were statistically
significant in males. When the interaction with the TFRC genotype and the gender effect
was considered, a more robust statistically significant association was found, as in a
previous study [9]. The same interaction was also observed in multiple cancers without a
gender effect [1,2]. While interaction analysis is usually seen as a challenge in terms of
statistical power, as happened in the present study, the increase in the effect size may
compensate for the loss of statistical power due to comparison of smaller subsets of the
sample. Like any statistical association, our results should be considered cautiously.
However, similarities with previous observations provide sufficient credibility to the
cumulative results, which now strongly suggest that iron excess, whether
environmentally- or genetically-induced increases the risk for cancer in general, and in
particular childhood ALL. As previously postulated [9,19], the mechanism of the
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childhood ALL risk association with HFE variants known to elevate body iron levels
may include increased materno-fetal iron transport through placenta. This process is
mediated by HFE and TFRC [20,21], and these genetically-mediated alterations in fetal
iron homeostasis may also have implications on the developmental origins of health and
disease [22].
Another novel finding of the present study was the risk associations of previously
unexamined IRG SNPs (rs422982 and rs733655) with childhood ALL. Together with the
association of rs855791, a GWAS identified marker for iron levels, which reached
statistical significance only in males, these new findings lend support to our hypothesis
that iron homeostasis related risk modification in childhood ALL extend beyond
HFE/TFRC polymorphisms. We do not yet know whether the SNPs selected by us and
used in any association study for the first time have any correlation with body iron levels.
Their locations in crucial IRGs suggest that they will be somewhat involved in some
aspect of gene function and subsequently in iron homeostasis, but only functional studies
can confirm their roles. The lack of statistical interaction between these additional SNPs
and the TFRC SNP suggested the specificity of the HFE and TFRC interaction. We were
not surprised by the lack of interaction between SLC11A2 / TMPRSS6 and TFRC since
they do not interact biologically.
The present study highlights the benefits of explorations of effect modification by
gender or ethnicity. Although such explorations are usually reserved for well powered
studies, when backed up by previous observations or strong biological hypotheses,
stratified analyses complemented by statistical interaction analyses are powerful
approaches to unravel otherwise masked associations. It is only natural that in a
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multigenic disorder like cancer, effect modification, which can be seen as multicausality,
will be operational. Researchers usually shy away from analysis of effect modification or
statistical interaction to avoid performing multiple comparisons and subsequent chance
findings, but there are ways to rule out chance findings by additional replication studies.
Besides the limitations already mentioned such as sample size and statistical
power, our study has another limitation, which has stemmed from one of its strengths.
Examination of these associations in a multi-ethnic cohort has benefits, but also brings
about heterogeneity, which should be accounted for during analysis. We had self-reported
race/ethnicity data, but adjustment of the results by these data may still leave some
residual confounding. We also used two AIMs to make sure that the heterogeneity in the
population will not result in spurious findings. The current practice in well-resourced
GWAS studies is to use thousands of AIMs to adjust genetic ancestry, which is
particularly crucial when the sample includes recently admixed populations such as
African Americans or Hispanics. We could not do that, but could include a couple of
AIMs to control for population heterogeneity. Another limitation of using a multi-ethnic
sample was the constraints it adds on checking genotyping error. We followed the usual
safeguards of genotyping error avoidance at the experimental phase, and checked for
errors at the analysis phase by using Hardy-Weinberg equilibrium testing. This test,
however, has to be done in each race/ethnicity subgroup separately. This practice further
reduces the statistical power of this test and may have caused inefficiency of genotyping
error checking. Genotyping errors have the potential to cause both false positives and
false negatives. Our results basically replicated previously observed associations, and

70

there is no overwhelming reason to consider genotyping errors as an alternative
explanation.
By replicating the HFE and TFRC interaction in childhood ALL risk association
and revealing new associations with IRGs, our study provided further evidence for the
hypothesis on the iron connection in childhood ALL susceptibility. These findings have
far reaching implications beyond childhood leukemia in the cancer field. We hope that
our results will stimulate interest in secondary analyses of existing GWAS data on
multiple cancers to explore the pathways involved in iron homeostasis. We also report
novel associations with gender or ethnicity specificity. These associations can also be
replicated using already existing datasets. Since no childhood ALL GWAS dataset is
currently available through public databases, we could not try replication, but we hope to
be able to do so in the future as databases become available for additional analysis.
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Table I. Characteristics of cases and controls

Ethnic background
Non-Hispanic White
Hispanic White
Black
Other*
Gender
Male
Female
Ratio
*

Cases
n=161

Controls
n=231

66
72
17
6

49
98
78
6

86
75
1.15

130
101
1.29

Asian, Native American, or other

75

P value

<0.001

0.58

Table II. Main features of SNPs analyzed

SNP

Chromosome nucleotide
position*

Minor allele and
frequency†

HFE

rs1800562

chr6: 26093141

(A) 0.053

Transition substitution,
missense mutation

C___1085595_10

HFE

rs1799945

chr6: 26091179

(G) 0.179

Missense mutation, transversion
substitution

C___1085600_10

TFRC

rs3817672

chr3: 195800811

(G) 0.383

Transition substitution, missense
mutation

C___3259537_10

SLC11A1

rs422982

chr12: 51406354

(A) 0.246

Transversion substitution,
intragenic

C____570333_10

TMPRSS6

rs733655

chr22: 37495051

(C) 0.221

Transition substitution, intragenic

C___3289858_1_

TMPRSS6

rs855791

chr22: 37462936

(T) 0.412

Transition substitution, missense
mutation

C___3289902_10

LPL

rs285

chr8: 19815189

(T) 0.500

Transition substitution, intragenic

C__12104266_10

ITGAE

rs2891

chr17: 3705526

(G) 0.496

Transition substitution, intragenic

C___3211308_20

Gene

SNP Type

Assay ID

*

Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/)

†

Minor allele frequencies are from a reference Caucasian population (U.S. residents of northern and western European ancestry) genotyped in HapMap

project

76

Table III. Univariable analyses of associations with childhood ALL risk*

*

SNP

OR
(95% CI)

P value

HFE rs1800562

1.37
(0.52 to 3.60)

0.52

HFE rs1799945

1.33
(0.74 to 2.38)

0.35

TFRC rs3817672

0.8
(0.52 to 1.23)

0.31

SLC11A2 rs422982

1.55
(1.01 to 2.37)

0.04

TMPRSS6 rs733655

2.06
(1.33 to 3.20)

0.001

TMPRSS6 rs855791

1.41
(0.91 to 2.18)

0.12

Adjusted for self-reported ethnicity and race (non-Hispanic White, Hispanic White, Blacks and others)
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Table IV. HFE and non-HFE associations with childhood ALL in gender and
race/ethnicity groups (ORs and 95% CIs)

HFE rs1800562

Females

Males

Non-Hispanic
Whites

Hispanic Whites

0.4

3.41

1.78

0.91

Pinteraction = 0.09
HFE rs1799945

1.01

Pinteraction = 0.55
1.51

1.26

Pinteraction = 0.78

TFRC rs3817672

Pinteraction = 0.56

1.66

0.7

2.54
(1.05 to 6.12)
P = 0.04

1.58

1.52

1.56

2.6
(1.44 to 4.70)
P = 0.002

Pinteraction = 0.61
2.35
(1.07 to 5.16)
P = 0.03

Pinteraction = 0.19

TMPRSS6 rs855791

1.12

1.91
(1.04 to 3.51)
P = 0.04

Pinteraction = 0.40
*

1.91
(0.99 to 3.68)

1.47

Pinteraction = 1.00

TMPRSS6 rs733655

0.69

Pinteraction = 0.02

Pinteraction = 0.21
SLC11A2 rs422982

0.87

2.52
(1.26 to 5.04)
P = 0.009

Pinteraction = 0.90

1.71

1.22

Pinteraction = 0.52

Adjusted for self-reported ethnicity and race (non-Hispanic White, Hispanic White, Blacks and others).
P values for individual analyses are only shown when <0.05
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Figure I. Risk genotype frequencies with pooled HFE association in childhood ALL in case and control groups, by
gender and TFRC genotype group
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4.5
4

Odds Ratio

3.5
3

P = 0.002

Overall

2.5

Males

2
P = 0.003

1.5
1

0

1

2

Number of IRG variants - Pooled
0 = no variants, 1 = one or two variants, 2 = three+ variants

Figure II. Polygenic risk variable consisting of five IRG SNPs and childhood ALL risk
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CHAPTER VI
BIRTH CHARACTERISTICS AND CHILDHOOD LEUKEMIA RISK:
CORRELATIONS WITH GENETIC MARKERS
Abstract
Birth characteristics such as birth order, birth weight, birth defects, and Down
syndrome showed some of the first risk associations with childhood leukemia. Besides
these non-genetic factors, recent genetic association studies have also identified markers
for susceptibility. Examinations of correlations between birth characteristics and
leukemia risk markers have been limited to birth weight-related genetic polymorphisms.
We aimed to revisit associations of birth characteristics with childhood acute
lymphoblastic leukemia (ALL) as well as their correlations with selected ALL risk
markers to integrate information on non-genetic and genetic markers. The study sample
was multi-ethnic/racial consisting of cases with childhood (≤18yr) ALL (n=161) and
healthy controls (n=261) recruited contemporaneously between 2007 and 2012. Nongenetic data on birth weight, birth length, and gestational age were collected through
administration of questionnaires, and genetic markers were genotyped using TaqMan
allelic discrimination assays. We observed risk associations for having a birth weight of
over 4,000 grams compared with being less than 4,000 grams (OR = 1.93, 95% CI = 1.16
to 3.19, P = 0.01), birth length (OR = 1.18 per inch, 95% CI = 1.01 to 1.38, P = 0.04),
and with gestational age (OR = 1.10 per week, 95% CI = 1.00 to 1.21, P = 0.04). None of
the associations interacted with gender or ethnicity. When we examined correlations
between these birth characteristics and genetic markers, only the HFE tagging SNP
rs9366637 showed an inverse correlation with gestational age with a gene-dosage effect
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(P = 0.005) and in interaction with a transferrin receptor (TFRC) rs3817672 genotype
(Pinteraction = 0.05). This correlation was translated into a strong association for this SNP
with preterm birth (gestational age ≤ 37 weeks) with five of ten subjects born preterm
being positive for the variant allele of rs9366637 (OR = 5.0, 95% CI = 1.19 to 20.9, P =
0.03). The strong interaction with TFRC suggests that rs9366637 may be involved in the
modification of HFE-mediated placental iron transfer. Our study provides evidence for
the involvement of prenatal events in the development of childhood ALL. The inverse
correlation of HFE rs9366637 with gestational age has implications on the design of HFE
association studies in birth weight and childhood conditions using full-term newborns as
controls. If this statistical association is confirmed and its biological mechanisms include
iron homeostasis changes, as suggested by our findings, the use of iron supplementation
during pregnancy may need to be more targeted.
Introduction
Birth order, birth weight, birth defects, and Down syndrome were among the first
risk factors shown to be associated with childhood leukemia risk [1-3]. Subsequent
studies have established Down syndrome, increased birth weight, and several congenital
disorders as consistent risk factors for childhood acute lymphoblastic leukemia (ALL)
[4,5]. More limited data are available on the suggestive associations of being first-born,
maternal age and miscarriages in maternal reproductive history with childhood ALL [5].
Of these, only the molecular mechanism of Down syndrome association has been
established [6]. Birth weight shows a consistent positive association with childhood ALL
that has been confirmed by meta-analyses [7-9]. Several biological mechanisms for the

82

birth weight association have been speculated [10-12], but none have been established
firmly.
Although a number of studies have examined the associations of birth
characteristics with childhood ALL [10,13-20] and adult cancer risk [21], few examined
the correlations between genetic risk markers and birth characteristics, mainly birth
weight [22]. Those studies that did examine genetic risk factors used polymorphisms
previously identified in genome-wide association studies (GWAS) and mostly yielded
negative results. The importance of the examination of birth characteristics in childhood
ALL research stems from recent evidence suggesting a prenatal origin for childhood ALL
development [23-26], and more broadly the concept of developmental origins of health
and disease [27-29].
Our aim was to examine associations of birth characteristics with childhood ALL
as well as their correlations with selected risk markers for childhood ALL to integrate
information on non-genetic and genetic markers. We had data on birth weight, birth
length, and gestational age, and we included a representative set of risk markers
previously identified in GWAS, HLA region markers due to the association of HLA
region polymorphisms with birth weight [30-33], iron regulatory gene HFE
polymorphisms previously shown to correlate with birth weight [11] and additional ironregulatory genes for their potential associations with birth characteristics. Since our
sample was multi-ethnic/racial, we also explored heterogeneity among non-Hispanic
Whites and Hispanics in any association observed.
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Subjects & Methods
Subjects
Institutional Review Board (IRB) approval was received at the Baylor College of
Medicine (BCM) and Florida International University prior to the start of the research
project. Subjects were recruited at Texas Children’s Hospital in Houston, TX. The study
was originally designed as a leukemia association study. The case-control group
consisted of 161 incident childhood ALL cases and 231 healthy age-matched controls
contemporaneously recruited at Texas Children’s Hospital general pediatrics clinics. The
children were less than 18 years of age at diagnosis, and exclusion criteria for both
groups included refusal to participate in the study and the diagnosis of any other disease
or cancer. Subjects and their parents were approached to acquire informed consent and
epidemiological data with a questionnaire and a biological sample, thus the gestational
age data was not record-based. DNA samples were obtained from either saliva or
peripheral blood samples at Texas Children’s Hospital. Parents were asked to provide
race (White, Black/African American, Asian, American Indian/Alaska Native, or Native
Hawaiian/Other Pacific Islander) and ethnicity (Hispanic/Latino or non-Hispanic/Latino)
of the child.
Genotyping
Genotyping was completed on the Bio-Rad CFX96 real-time PCR machine
(Hercules, CA) using Life Technologies TaqMan® single nucleotide polymorphism
(SNP) genotyping assays (LifeTech, Foster City, CA). The singleplex reactions were
carried out in 96-well plates and used Bio-Rad’s SsoFast™ Probes Supermix as the
reaction buffer. PCR amplifications were performed using the manufacturer’s suggestion
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of total volume/well and PCR thermal cycling conditions. SNPs of interest are listed in
Table I together with their features. SNPs included were: established ALL risk markers in
previous GWAS, HFE SNPs known to correlate with body iron levels, another IRG SNP
that shows a very high correlation with serum iron parameters in GWAS, and two
additional IRG SNPs selected by us as haplotype tagging SNPs for the promoter regions
of two IRGs. We also included three HLA region SNPs known to modify lymphoma risk,
one being the marker for the HLA-DRB4 lineage [34], which is also associated with risk
for major leukemia types, as previously shown in candidate gene studies [35-39]. Two
additional SNPs (rs285 and rs2891) were included as ancestry informative markers
(AIMs) for statistical adjustment of ethnicity and race as has been used in Hispanic
populations to account for the differences in genetic ancestry [40,41]. Bio-Rad CFX
Manager software (version 3.0) was used for data acquisition and genotype assignment.
Statistical analysis
Statistical analyses were performed using Stata v.11 (StataCorp, College Station,
TX, USA). Logistic regression was used to explore the associations of birth
characteristics (birth weight, birth length, gestational age) with childhood ALL risk.
Linear regression was used to assess correlation of genetic markers with continuous birth
characteristic variables. The threshold for statistical significance was set at P ≤ 0.05, and
95% confidence intervals (CI) of odds ratios (OR) were computed. Pearson’s Χ2,
Student's t-test (for means) or median test (for medians) were used to compare
characteristics between the case and control groups. Genotype counts were tested for
Hardy–Weinberg equilibrium (HWE) in controls for each SNP. Correlations with genetic
markers were assessed using the dominant model in which polymorphic allele carrying
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genotypes are coded as 1 and the wildtype (common allele homozygote) genotype is
coded as 0. When a SNP association was found, gene-dosage effect was explored by
using the additive genetic model which uses all three genotypes coded as 0, 1 and 2
reflecting the number of polymorphic alleles present in the genotype. For most analyses,
cases and controls were pooled to increase statistical power, but only after ruling out
heterogeneity. As the sample was heterogeneous in its ethnic/racial composition, and
genetic markers show variation in these groups, all results are adjusted for self-declared
ethnic/racial groups (coded as non-Hispanic Whites, Hispanic Whites, Blacks and
others). To rule out residual confounding, two SNPs were also used for adjustments,
individually, to check whether the results were changed after adjustment for genetic
ancestry.
Results
Characteristics of the case-control sample are shown in Table II. The case
samples included 86 males (53%) and 75 females (47%). Out of the cases, 66 identified
themselves as non-Hispanic White (NHW), 72 as Hispanic White (HW), 17 as Black, and
6 as “other.” The “other” group included those identifying themselves as Asian, Native
American, or other. The controls included 130 males (56%) and 101 females (44%), who
had visited the pediatric clinic for a non-disease related reason. Forty-nine were classified
as NHW, 98 as HW, and 78 as Black. The distribution of race and ethnic background was
different between cases and controls, mainly due to the infrequency of childhood ALL in
Blacks. Because of this difference, results were adjusted for racial/ethnic background or
stratified analyses were performed when necessary. The differences in birth
characteristics between cases and controls are detailed below.
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Birth weight
There was no association between childhood ALL and birth weight when the birth
weight variable was retained as a continuous variable. Since most studies reported a risk
association with birth weight of 4,000 grams or higher, we categorized the variable as
high birth weight (≥4,000g) - others (<4,000g), and re-examined the association. There
was a statistically significant association with high birth weight in the overall group (OR
= 1.93, 95% CI = 1.16 to 3.19, P = 0.01, adjusted for self-declared ethnicity/race).
Although there was no statistical interaction with gender or ethnicity, among the
subgroups, the association reached statistical significance in males and in Hispanics. The
OR was as high as 3.18 (95% CI = 1.16 to 8.73, P = 0.02) in Hispanic males. The overall
association with high birth weight did not change when adjusted for each AIM instead of
self-declared ethnicity/race. The association with birth weight could not be attributed to
gestational age heterogeneity, and adjustment for gestational age or restriction of the
analysis to subjects born at or later than 38 weeks of gestational age did not result in a
substantial change in the OR of the association. By categorizing the birth weight variable
into three groups (<2500g; 2500-3999g; ≥4000g), the overall association and association
in males remained statistically significant (data not shown).
Birth length
As a continuous variable, birth length showed an overall association with
childhood ALL risk (OR = 1.18 per inch, 95% CI = 1.01 to 1.38, P = 0.04). Among the
subgroups, this association was statistically significant in females and in non-Hispanic
Whites, but there was no statistical interaction with gender or ethnicity. In non-Hispanic
White females, the OR was 1.81 (95% CI = 1.03 to 3.18, P = 0.04). Restricting the
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analysis to subjects born at gestational age 39 week or later (full-term) did not weaken
the results. On the contrary, the OR in the whole group became 1.25, and 3.03 in nonHispanic females, both remaining statistically significant.
Gestational age
In the overall group, there was a risk association with gestational age (OR = 1.10
per week, 95% CI = 1.00 to 1.21, P = 0.04, adjusted for ethnicity/race). This association
did not interact with gender or ethnicity/race although it was stronger in females and in
Hispanics with the OR reaching 1.43 (95% CI = 1.09 to 1.87, P = 0.009). Categorization
of the gestational age variable into three groups (<38 wk; 38wk; >38wk) resulted in the
loss of statistical significance for the association.
Correlation of birth characteristics with genetic markers
Having found associations between birth characteristics and childhood ALL risk,
we sought correlations between the birth characteristics and SNPs included in this study.
For these analyses, the birth weight variable was used as high birth weight (≥4,000g)
versus others; and birth length and gestational age variables were used as continuous
variables. Correlations were sought in the whole group as well as in the subgroup that
showed the strongest leukemia association. We were able to show a correlation for only
one genetic marker and gestational age. HFE tagging SNP rs9366637 showed a
significant negative correlation with a gene-dosage effect (P=0.005) with gestational age.
Males had a stronger negative correlation (P=0.001) with this variant. There was no
association in females (P=0.98), and the interaction with gender reached statistical
significance (Pinteraction=0.02 for gender). No heterogeneity was found when analyzing the
case and control groups separately. In fact, the regression coefficients were larger in the
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control group. Replacing the self-declared ethnicity/race variable with either AIM for
adjustment did not alter the results. The average gestational age showed a stepwise
change with increasing number of rs9366637 variant alleles, with the mean gestational
age decreasing from 38.6 weeks (homozygous wild-type) to 36.7 weeks (homozygous
variant) (Figure I, Graph A).
Because of the known biological relationship between HFE and TFRC, rs3817672
was genotyped, and the interaction between rs3817672 and rs9366637 variant alleles was
assessed. There was a significant statistical interaction between them (Pinteraction=0.02).
Overall, the negative association between rs9366637 and decreasing gestational age
increased in statistical significance (P=0.001), and the male subgroup again showed the
strongest negative correlation (P<0.001) in subjects with the particular TFRC genotype.
Figure I depicts the mean gestational age by HFE rs9366637 and TFRC rs3817672
genotypes. Bar graph A in Figure I shows the gestational age means for just the HFE
variant on its own, in the overall group. Graphs B and C depict the gestational age means
for the HFE variant depending on the TFRC genotype (AA in Graph B and AG/GG
combined in Graph C). Lastly, bar graphs D and E show the mean gestational age for
males (D) and females (E) who had the HFE and TRFC genotypes that jointly showed the
strongest correlation with gestational age (Pinteraction = 0.001).
We also examined the association of the HFE SNP rs9366637 with preterm birth
defined as gestational age less than 37 weeks. Despite very small number of preterm
births in the overall sample (n=65), there was an association between this SNP and
preterm birth in non-Hispanic White males (P = 0.03), which was due to five of ten
preterm males being positive for the variant allele of rs9366637.
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Discussion
This study observed a birth weight association with childhood ALL risk [7-9], and
novel associations with birth length and gestational age. While birth length association
may be due to similar mechanisms as the birth weight association, the gestational age
association is novel. The birth weight association is well known in childhood ALL, and
fetal growth rate is probably even more crucial [9], but we were not able to assess fetal
growth rate due to sample size limitations. Another novel finding was the inverse
correlation between an HFE SNP and gestational age. This association showed genderspecificity, gene-dosage effect and a statistical interaction with another genotype that has
biological basis. This is a novel finding worth pursuing in future research, as it may lead
to development of a marker with some clinical utility.
The HFE SNP rs9366637 (IVS1) has not been studied as extensively as the other
HFE variants rs1800562 (C282Y) or rs1799945 (H63D), and has not been directly
implicated in iron regulation. It has shown a weak correlation with birth weight [11] and
a strong association with adult height [42]. In a case-control study in a Han Chinese
sample, the variant allele for rs9366637 was also found to be a significant risk marker for
coronary heart disease (CHD) [43]. The haplotype tagged by this SNP is always devoid
of the two variants C282Y and H63D that are associated with increased iron levels and
presumably increased iron placental transfer. Since rs9366637 is a tagging SNP, we
explored polymorphisms tagged by rs9366637 to see if any were functional and/or
previously assessed (Table III). We were not able to attribute any functionality to any of
the tagged SNPs for which rs9366637 is a proxy, nor was there any published disease
associations with any of these SNPs.
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The inverse correlation found between rs9366637 and gestational age, and its
interaction with TFRC brings speculation on whether this SNP is also involved in iron
homeostasis. There is no known effect with this SNP on HFE function, but being positive
for this SNP would assure the lack of H63D or C282Y on the same chromosome
negatively affecting placental iron transfer. Thus, if the association of rs9366637 is due to
its modification of HFE function, it is more likely to be not facilitating iron transfer into
the developing fetus.
The risk association of rs9366627 and CHD in a Han Chinese population where
the minor allele frequency is much higher than in European populations may be
consistent with its association with preterm birth [43]. Babies born before term are also
low birth weight and at high risk for cardiovascular diseases later in life [27]. This issue
has been recently revisited and nutrition of preterm babies with special formula and
accelerated growth in very early life have been considered in the pathogenesis of later
development of disease in preterm babies [44]. It is important to note that rs9366637 is
also associated with body height in adults [42], and may predispose babies to accelerated
growth. Although our findings are purely statistical correlations, future studies should
explore potential implications of these findings.
We included the interaction analysis of the TFRC variant rs3817672 with HFE
variant rs9366637 to see if a gene-gene interaction existed. The presence of the TFRC
“A” allele was associated with increased risk for preterm birth in rs9366637 variantpositive individuals, specifically males. Interactions between HFE and TFRC allele “G”
have also been noticed in various cancers, including multiple myeloma, breast, and
colorectal cancer [45] as well as childhood ALL [11]. Since the HFE interaction with
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TFRC allele G is believed to increase iron transport leading to increased birth weight [11]
and cancer risk [46], it is important to note that the interaction of rs9366637 was with
TFRC allele A in its association with shorter gestational age. This contrast suggests that
the inverse correlation with gestational age, if causal, is likely to be due to insufficient
iron transfer to the fetus. Iron deficiency is indeed a known risk factor for preterm birth
[47].
There were important limitations with our study, including sample size. We were
able to pool the cases and controls (n=392) to gain statistical power, since cases and
controls did not show statistical heterogeneity for the correlation with the HFE SNP.
Gestational age was provided by the mother of the child enrolled in the study through a
questionnaire. Previous studies, however, have shown a high correlation between birth
weight, gestational ages, and other birth characteristics provided by the mother of a
patient and medical chart recordings [17, 48]. Non-differential measurement error may
have occurred, causing towards-the-null bias, if not all gestational ages were correctly
recalled. Missing data was another limitation in our study, with 88% of the total group
having gestational age data.
Results from this study raise an important issue in study designs for future
childhood studies. Most studies of a childhood disease consist of a control group
comprised of full term babies and include as many cases as possible, regardless of their
birth term. By doing this, the control group could be missing a whole group of children
who may be carriers of certain variant genetic markers. Variants that may be associated
with non-term births would be eliminated from the control group. The outcome of this
mistake could lead to spurious results.
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In conclusion, the HFE variant rs9366637 has shown a statistically significant
negative correlation with gestational age. The SNP rs9366637, which is not known to be
involved with iron homeostasis, showed a positive interaction with a TRFC genotype and
yielded a stronger association with shorter gestational age, specifically in males. This
correlation may reveal a connection between altered placental iron transfer and the risk of
preterm birth. Since our study did not observe other correlations between a number of
genetic markers and birth characteristics investigated, this may be another area that needs
to be addressed in larger and more comprehensive studies, ideally using a GWAS design.
If our results are validated in different populations, the findings will have implications on
iron supplementation strategies during pregnancy.
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Table I. Main features of SNPs analyzed
SNP

Chromosome nucleotide
position*

Minor allele and
frequency**

HFE

rs1800562

chr6: 26093141

(A) 0.053

Transition substitution, mis-sense mutation

HFE

rs1799945

chr6: 26091179

(G) 0.179

Mis-sense mutation, transversion substitution

HFE

rs9366637

chr6: 26089098

(T) 0.064

Intronic; transition substitution

TFRC

rs3817672

chr3: 195800811

(G) 0.383

Transition substitution, mis-sense mutation

SLC11A1

rs422982

chr12: 51406354

(A) 0.246

Transversion substitution, intragenic

TMPRSS6

rs733655

chr22: 37495051

(C) 0.221

Transition substitution, intragenic

Gene

*

SNP Type

TMPRSS6

rs855791

chr22: 37462936

(T) 0.412

Transition substitution, mis-sense mutation

ARID5B

rs7089424

chr10: 63752159

(G) 0.314

Intronic

ARID5B

rs10821936

chr10: 63723577

(C) 0.318

Intronic

ARID5B

rs10994982

chr10: 63710104

(A) 0.457

Intronic

IKZF1

rs4132601

chr7: 50470604

(G) 0.306

3'-UTR

CEBPE

rs2239633

chr14: 23589057

(A) 0.466

5'-upstream

HLA-DR region

rs2395185

chr6: 32433167

(T) 0.423

Intronic

HLA-DQB1 region

rs2647012

chr6: 32664458

(T) 0.381

Intergenic

HLA-DQA1 region

rs10484561

chr6: 32665420

(G) 0.084

Intergenic

LPL

rs285

chr8: 19815189

(T) 0.500

Transition substitution, intragenic

ITGAE

rs2891

chr17: 3705526

(G) 0.496

Transition substitution, intragenic

Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position (http://www.ncbi.nlm.nih.gov/SNP/)

**

Minor allele frequencies are from a reference Caucasian population (U.S. residents of northern and western European ancestry) genotyped in HapMap
project
††
IVS1: intervening sequence 1 SNP
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Table II. Characteristics of cases and controls
Cases
n=161

Controls
n=231

66
72
17
6

49
98
78
6

86
75
1.15

130
101
1.29

0.58

3349.3 (584)
3400 (760)

3263.3 (684)
3311.5 (850)

0.23
0.48

Gestational age (weeks) (SD)

38.8 (2.2)

38.2 (2.8)

0.04

Birth length (cm) (SD)

51.4 (3.4)

50.1 (5.05)

0.024

Ethnic background
Non-Hispanic White
Hispanic White
Black
Other*
Gender
Male
Female
Ratio
Birth weight (grams)
Mean (SD)
Median (IQR)

*

Asian, Native American, or other
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P value

<0.001

Table III. HFE rs9366637 and its tagging SNPs

*

Proxy

Distance

r2*

Chr.

Nucleotide
number

SNP Location

rs9366637

0

1.000

6

26089098

Intronic

rs2050947

19019

1.000

6

26070079

Intergenic

rs9295682

19604

1.000

6

26069494

Intronic

rs9379826

23058

0.892

6

26112156

Intergenic

rs9393682

32048

0.892

6

26165029

Intergenic

An indication of the correlation with rs9366637; scale of 0-1 with 1 denoting maximum correlation

100

Figure I. Gene-gene and gene-gene-gender interactions in gestational age association of HFE rs9366637
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CHAPTER VII
CONCLUSIONS AND FUTURE RESEARCH
Conclusions
This dissertation research was conducted to explore the correlations among
genetic polymorphisms, birth characteristics, and the risk of childhood ALL. The
replication of GWAS childhood leukemia markers [1,2] validated our case-control group
and added credibility to the results of our present project. The genotyping of HLA region
lymphoma risk markers not only confirmed a previous male-only strong risk association
from rs2395185 [3], but also identified new risk markers for childhood ALL. All
significant associations with lymphoma risk markers were in opposite risk direction
compared to the lymphoma association studies. HLA region marker rs2647012 was found
to be a significant risk only in Hispanics, and rs1048456, a risk marker in follicular
lymphoma showed a statistically significant protective association.
Our hypothesis that iron-regulatory gene (IRG) variants known to elevate iron
levels increase childhood ALL risk was driven by previous research, which showed a
male-specific childhood ALL risk [4-6], and the biological implications showing iron
excess associated with other cancers [7-11]. We examined the effect modification by
gender and race/ethnicity in childhood ALL susceptibility, and also looked into genegene interactions to test our hypotheses.
The main objective of re-examining the association with HFE variants and
childhood ALL susceptibility was accomplished. Our results not only replicated previous
HFE risk associations with childhood ALL [4,5], but by extending similar findings to
other IRG SNPs, strengthened the hypothesis that iron excess mediated by genetic
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variants contributes to childhood ALL risk. It was previously known that HFE variants
that correlate with body iron levels show associations with cancer risk, including
childhood ALL [4,5], and also show a correlation with birth weight. Our results
confirmed this leukemia risk, with replication of the male-only association [4,5].
Birth characteristics such as birth weight, height, and gestational age were
examined to see if correlations with childhood ALL existed. Birth length showed an
overall risk association with childhood ALL, with females and non-Hispanic Whites
showing significance among the subgroups. There was no statistical interaction with
gender or ethnicity, however. The correlation between birth weight and childhood ALL
[12,13] was evident when comparing those having a birth weight of over 4,000 grams
with those less than 4,000 grams. No individual SNP showed a correlation with birth
length or birth weight. A novel significant risk association with gestational age overall
did not interact with gender or ethnicity/race, although it was stronger in females and in
Hispanics.
Correlations between HFE SNPs and gestational age were also examined. A
significant negative correlation was found with the HFE variant rs9366637, more
robustly among males. The inverse correlation of rs9366637 with gestational age has
implications on the design of HFE association studies in birth weight and childhood
conditions using newborns as controls.
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Future Research
As with any epidemiological study, and especially important with genetic
association studies, there is a need for replication and follow up studies to ensure the
findings are valid [14-16]. Our conclusions are based on statistical correlations, therefore
properly executed genetic and functional replication studies are necessary. Proper study
design addressing the sample size issue for a rare disease like childhood ALL is crucial in
follow up studies.
Our conclusions require independent replications done properly; meaning the
methods of analysis should be consistent. A recent publication failed to replicate the HFE
variant risk association with childhood ALL [17]. The researchers did not take into
account gender effect and gene-gene interactions that are stated in the parent study,
therefore the results are not a true replication failure of the original study.
The only way to confirm our hypotheses would be to examine pre-diagnostic iron
levels, making cohort studies a necessity. Even as unrealistic and unfeasible as it may
seem because childhood ALL is such a rare disease, ideally a cohort study would be best
for this research. Any replication should be done in an international collaboration format
as well, so that the sample size is increased, therefore statistical power for more robust
and credible results would also increase. Both of these criteria are achievable because of
the Childhood Leukemia International Consortium (CLIC), a giant international
consortium that pools data from independent studies from 12 countries across the world
[18].
Our research is significant in terms of both population health and in scientific
advancements. Results may indicate a possible biological mechanism of the role iron
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plays in the cancer association, leading to an impact on both child and maternal health.
Educating the public on lifestyle modifications for preventive measures, such as
controlled iron supplementation during pregnancy, unregulated access to iron-containing
multivitamins, and avoidance from the unnecessary consumption of iron-rich food, could
reduce the risk of leukemia in children.
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